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Abstract 28 
During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed 29 
hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain 30 
(RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that 31 
antibodies will be essential for protection. However, little is known about the human 32 
antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19 convalescent 33 
individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable 34 
half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%, 35 
while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-36 
specific memory B cells expressing closely related antibodies in different individuals. Despite 37 
low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal 38 
inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent 39 
plasmas obtained from individuals who recover from COVID-19 do not contain high levels 40 
of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent 41 
antiviral activity were found in all individuals tested, suggesting that a vaccine designed to 42 
elicit such antibodies could be broadly effective.   43 
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Between April 1 and May 8, 2020, 157 eligible participants enrolled in the study. Of these, 111 44 
(70.7%) were individuals diagnosed with SARS-CoV-2 infection by RT-PCR (cases), and 46 45 
(29.3%) were close contacts of individuals diagnosed with SARS-CoV-2 infection (contacts). 46 
While inclusion criteria allowed for enrollment of asymptomatic participants, 8 contacts that did 47 
not develop symptoms were excluded from further analyses. The 149 cases and contacts were free 48 
of symptoms suggestive of COVID-19 for at least 14 days at the time of sample collection. 49 
Participant demographics and clinical characteristics are shown in Table 1 and Extended Data 50 
Tables 1 and 2. Only one individual who tested positive for SARS-CoV-2 infection by RT-PCR 51 
remained asymptomatic. The other 148 participants reported symptoms suggestive of COVID-19 52 
with an average onset of approximately 39 days (range 17 to 67 days) before sample collection. In 53 
this cohort, symptoms lasted for an average of 12 days (0-35 days), and 11 (7%) of the participants 54 
were hospitalized. The most common symptoms were fever (83.9%), fatigue (71.1%), cough 55 
(62.4%) and myalgia (61.7%) while baseline comorbidities were infrequent (10.7%) (Table 1 and 56 
Extended Data Tables 1 and 2). There were no significant differences in duration or severity (see 57 
Methods) of symptoms, or in time from onset of symptoms to sample collection between genders 58 
or between cases and contacts. There was no age difference between females and males in our 59 
cohort (Extended Data Fig. 1). 60 
 61 
Plasma samples were tested for binding to the SARS-CoV-2 RBD and trimeric spike (S) proteins 62 
by ELISA using anti-IgG or -IgM secondary antibodies for detection (Fig. 1, Extended Data Table 63 
1 and Extended Data Figs. 2 and 3). Eight independent negative controls and the plasma sample 64 
from participant 21 (COV21) were included for normalization of the area under the curve (AUC). 65 
Overall, 78% and 70% of the plasma samples tested showed anti-RBD and anti-S IgG AUCs that 66 
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were at least 2 standard deviations above the control (Fig. 1 a, b). In contrast, only 15% and 34% 67 
of the plasma samples showed IgM responses to anti-RBD and anti-S that were at least 2 standard 68 
deviations above control, respectively (Fig. 1 c, d). There was no positive correlation between anti-69 
RBD or -S IgG or IgM levels and duration of symptoms or the timing of sample collection relative 70 
to onset of symptoms (Fig. 1e, and Extended Data Figs. 3 a-c and 3 g-j). On the contrary, as might 71 
be expected, anti-RBD IgM titers were negatively correlated with duration of symptoms and the 72 
timing of sample collection (Fig. 1e and Extended Data Fig. 3h). Anti-RBD IgG levels were 73 
modestly correlated to age, and the severity of symptoms including hospitalization (Fig. 1 f, g and 74 
Extended Data Fig. 3k). Interestingly, females had lower anti-RBD and -S IgG titers than males 75 
(Fig. 1h, Extended Data Fig. 2f).    76 
 77 
To measure the neutralizing activity in convalescent plasmas we used HIV-1-based virions 78 
carrying a nanoluc luciferase reporter that were pseudotyped with the SARS-CoV-2 spike (SARS-79 
CoV-2 pseudovirus, see Methods, Fig. 2 and Extended Data Fig. 4). The overall level of 80 
neutralizing activity in the cohort, as measured by the half-maximal neutralizing titer (NT50) was 81 
generally low, with 33% undetectable and 79% below 1,000 (Fig. 2 a, b). The geometric mean 82 
NT50 was 121 (arithmetic mean = 714), and only 2 individuals reached NT50s above 5,000 (Fig. 2 83 
a, b and Extended Data Table 1).  84 
 85 
Notably, levels of anti-RBD- and -S IgG antibodies correlated strongly with NT50 (Fig. 2 c, d). 86 
Neutralizing activity also correlated with age, duration of symptoms and symptom severity 87 
(Extended Data Fig. 5). Consistent with this observation, hospitalized individuals with longer 88 
symptom duration showed slightly higher average levels of neutralizing activity than non-89 
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hospitalized individuals (p=0.0495, Fig. 2e). Finally, we observed a significant difference in 90 
neutralizing activity between males and females (p=0.0031, Fig. 2f). The difference between males 91 
and females was consistent with higher anti-RBD and -S IgG titers in males, and could not be  92 
attributed to age, severity, timing of sample collection relative to onset of symptoms or duration 93 
of symptoms (Fig. 1h, Extended Data Fig. 1 a-d and 2f).  94 
 95 
To determine the nature of the antibodies elicited by SARS-CoV-2 infection we used flow 96 
cytometry to isolate individual B lymphocytes with receptors that bound to RBD from the blood 97 
of 6 selected individuals including the 2 top and 4 high to intermediate neutralizers (Fig. 3). The 98 
frequency of antigen-specific B cells, identified by their ability to bind to both Phycoerythrin (PE)- 99 
and AF647-labeled RBD, ranged from 0.07 to 0.005% of all circulating B cells in COVID-19 100 
convalescents but they were undetectable in pre-COVID-19 controls (Fig. 3a and Extended Data 101 
Fig. 6). We obtained 534 paired IgG heavy and light chain (IGH and IGL) sequences by reverse 102 
transcription and subsequent PCR from individual RBD-binding B cells from the 6 convalescent 103 
individuals (see Methods and Extended Data Table 3). When compared to the human antibody 104 
repertoire, several IGHV and IGLV genes were significantly over-represented (Extended Data Fig. 105 
7). The average number of V genes nucleotide mutations for IGH and IGL was 4.2 and 2.8, 106 
respectively (Extended Data Fig. 8), which is lower than in antibodies cloned from individuals 107 
suffering from chronic infections such as Hepatitis B or HIV-1, and similar to antibodies derived 108 
from primary malaria infection or non-antigen-enriched circulating IgG memory cells6-8 (Wang et 109 
al, in press, https://www.biorxiv.org/content/10.1101/2020.03.04.976159v1.full). Among other 110 
antibody features, IGH CDR3 length was indistinguishable from the reported norm and 111 
hydrophobicity was below average (Extended Data Fig. 8)9.  112 
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 113 
As is the case with other human pathogens, there were expanded clones of viral antigen binding B 114 
cells in all COVID-19 individuals tested (see Methods and Fig. 3 b,c). Overall, 32.2% of the 115 
recovered IGH and IGL sequences were from clonally expanded B cells (range 21.8-57.4% across 116 
individuals, Fig. 3b). Antibodies that shared specific combinations of IGHV and IGLV genes in 117 
different individuals comprised 14% of all the clonal sequences (colored pie slices in Fig. 3 b,c). 118 
Remarkably, the amino acid sequences of some antibodies found in different individuals were 119 
nearly identical (Fig. 3 e,d). For example, antibodies expressed by clonally expanded B cells with 120 
IGHV1-58/IGKV3-20 and IGHV3-30-3/IGKV1-39 found repeatedly in different individuals had 121 
amino acid sequence identities of up to 99% and 92%, respectively (Fig. 3d and Extended Data 122 
Table 4). We conclude that the IgG memory response to the SARS-CoV-2 RBD is rich in recurrent 123 
and clonally expanded antibody sequences.      124 
 125 
To examine the binding properties of anti-SARS-CoV-2 antibodies, we expressed 84 126 
representative antibodies, 56 from clones and 28 from singlets (Extended Data Table 5). ELISA 127 
assays showed that 94% (79 out of 84) of the antibodies tested including clonal and unique 128 
sequences bound to the SARS-CoV-2 RBD with an average half-maximal effective concentration 129 
(EC50) of 6.1 ng/mL (Fig. 4a and Extended Data Fig. 9a). A fraction of those (7 out of 79, or 9%) 130 
cross-reacted with the RBD of SARS-CoV with a mean EC50 of 120.1 ng/mL (Extended Data Fig. 131 
9b and c). No significant cross-reactivity was noted to the RBDs of MERS, HCoV-OC43, HCoV-132 
229E or HCoV-NL63.  133 
 134 
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To determine whether the monoclonal antibodies have neutralizing activity, we tested them against 135 
the SARS-CoV-2 pseudovirus (Fig. 4 and Extended Data Table 6). Among 79 RBD binding 136 
antibodies tested, we found 40 that neutralized SARS-CoV-2 pseudovirus with nanogram per 137 
milliliter half-maximal inhibitory concentrations (IC50s) ranging from 3 to 709 (Fig. 4 b,c and e, 138 
Extended Data Table 6). A subset of the most potent of these antibodies were also tested against 139 
authentic SARS-CoV-2 and neutralized with IC50s of less than 5 ng/ml (Fig. 4 d,e).  140 
 141 
Potent neutralizing antibodies were found in individuals irrespective of their plasma NT50s. For 142 
example, C121, C144, and C135 with IC50s of 1.64, 2.55 and 2.98 ng/mL against authentic SARS-143 
CoV-2, respectively, were obtained from individuals COV107, COV47, and COV72 whose 144 
plasma NT50 values were of 297, 10,433 and 3,138, respectively (Figs. 2b and 4). Finally, clones 145 
of antibodies with shared IGHV and IGLV genes were among the best neutralizers, e.g., antibody 146 
C002 composed of IGHV3-30/IGKV1-39 is shared by the 2 donors with the best plasma 147 
neutralizing activity (red pie slice in Fig. 3b and Fig. 4). We conclude that even individuals with 148 
modest plasma neutralizing activity harbor rare IgG memory B cells that produce potent SARS-149 
CoV-2 neutralizing antibodies.    150 
 151 
To determine whether human anti-SARS-CoV-2 monoclonal antibodies with neutralizing activity 152 
can bind to distinct domains on the RBD, we performed bilayer interferometry experiments in 153 
which a preformed antibody-RBD immune complex was exposed to a second monoclonal. The 154 
antibodies tested comprised 3 groups, all of which differ in their binding properties from CR3022, 155 
an antibody that neutralizes SARS-CoV and binds to, but does not neutralize SARS-CoV-210,11. 156 
Representatives of each of the 3 groups include:  C144 and C101 in Group 1; C121 and C009 in 157 
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Group 2; C135 in Group 3. All of these antibodies can bind after CR3022. Groups 1 and 2 also 158 
bind after Group 3, and Groups 1 and 2 differ in that Group 1 can bind after Group 2 but not vice 159 
versa (Fig. 4 f-n). We conclude that similar to SARS-CoV, there are multiple distinct neutralizing 160 
epitopes on the RBD of SARS-CoV-2.   161 
 162 
To further define the binding characteristics of Groups 1 and 2 antibodies, we imaged SARS-CoV-163 
2 S–Fab complexes by negative stain electron microscopy (nsEM) using C002 (Group 1, an 164 
IGHV3-30/IGKV1-39 antibody, which is clonally expanded in 2 donors), C119 and C121 (both in 165 
Group 2) Fabs (Fig. 4 f-r and Extended Data Fig. 10). Consistent with the conformational 166 
flexibility of the RBD, 2D class averages showed heterogeneity in both occupancy and 167 
conformation of bound Fabs for both groups (Fig. 4o-q). The 3D reconstructions of S-Fab 168 
complexes revealed both a fully-occupied RBD and partial density for a second bound Fab, 169 
suggesting that Fabs from both groups are able to recognize “up” and “down” states of the RBD 170 
as previously described for some of the antibodies targeting this epitope12,13. The 3D 171 
reconstructions are also consistent with BLI measurements indicating that Groups 1 and 2 172 
antibodies bind a RBD epitope distinct from antibody CR3022, which is only accessible on the 173 
RBD “up” conformational state11, and bind the RBD with different angles of approach, with Group 174 
1 antibodies most similar to the approach angle of the SARS-CoV antibody S230 (Fig. 4r)14. 175 
    176 
Human monoclonal antibodies with neutralizing activity against pathogens ranging from viruses 177 
to parasites have been obtained from naturally infected individuals by single cell antibody cloning. 178 
Several have been shown to be effective in protection and therapy in model organisms and in early 179 
phase clinical studies, but only one antiviral monoclonal is currently in clinical use15. Antibodies 180 
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are relatively expensive and more difficult to produce than small molecule drugs. However, they 181 
differ from drugs in that they can engage the host immune system through their constant domains 182 
that bind to Fc gamma receptors on host immune cells16. These interactions can enhance immunity 183 
and help clear the pathogen or infected cells, but they can also lead to disease enhancement during 184 
Dengue17 and possibly coronavirus infections18. This problem has impeded Dengue vaccine 185 
development but would not interfere with the clinical use of potent neutralizing antibodies that can 186 
be modified to prevent Fc gamma receptor interactions and remain protective against viral 187 
pathogens19.  188 
 189 
Antibodies are essential elements of most vaccines and will likely be crucial component of an 190 
effective vaccine against SARS-CoV-220(PMID:32434945; PMID:32434946). Recurrent 191 
antibodies have been observed in other infectious diseases and vaccinal responses 21-24(Wang et 192 
al, in press, https://www.biorxiv.org/content/10.1101/2020.03.04.976159v1.full). The observation 193 
that plasma neutralizing activity is low in most convalescent individuals, but that recurrent anti-194 
SARS-CoV-2 RBD antibodies with potent neutralizing activity can be found in individuals with 195 
unexceptional plasma neutralizing activity suggests that humans are intrinsically capable of 196 
generating anti-RBD antibodies that potently neutralize SARS-CoV-2. Thus, vaccines that 197 
selectively and efficiently induce antibodies targeting the SARS-CoV-2 RBD may be especially 198 
effective.    199 
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Table 200 
  201 
Table 1.  Cohort characteristics
Gender n IgG IgM IgG IgM
45 12 39 5.8
(19-76) (0-31) (21-63) (0-10)
42 12 38 5.4
(19-75) (1-35) (17-67) (1-9)
Sx=symptoms
867
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Figures 202 
 203 
Figure 1. Plasma antibodies against SARS-CoV-2. a-d, Graphs show results of ELISAs 204 
measuring plasma reactivity to RBD (a, b) and S protein (c, d). Left shows optical density units at 205 
450 nm (OD, Y axis) and reciprocal plasma dilutions (X axis). Negative controls in black; 206 
individuals 21, and 47 in blue and red lines and arrowheads, respectively. Right shows normalized 207 
area under the curve (AUC) for controls and each of 149 individuals in the cohort. e, Symptom 208 
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(Sx) onset to time of sample collection in days (X axis) plotted against normalized AUC for IgM 209 
binding to RBD (Y axis) r=0.5517 and p=<0.0001. f, Participant age in years (X axis) plotted 210 
against normalized AUC for IgG binding to RBD (Y axis) r=0.1827 and p=0.0258. The r and p 211 
values for the correlations in e and f were determined by two-tailed Spearman’s. g, IgG anti-RBD 212 
normalized AUC for outpatients and hospitalized individuals p=0.0178. h, IgG anti-RBD 213 
normalized AUC for males and females p=0.0063. For g and h horizontal bars indicate median 214 
values. Statistical significance was determined using two-tailed Mann-Whitney U test.   215 
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 216 
Figure 2. Neutralization of SARS-CoV-2 pseudovirus by plasma. a, Graph shows normalized 217 
relative luminescence values (RLU, Y axis) in cell lysates of 293TACE2 cells 48 hours after 218 
infection with nanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasing 219 
concentrations of plasma (X axis) derived from 149 participants (grey, except individuals 47 and 220 
21 in red, and blue lines, bars and arrowheads, respectively) and 3 negative controls (black lines). 221 
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Standard deviations of duplicates of one representative experiment are shown. b, Ranked average 222 
half-maximal inhibitory plasma neutralizing titer (NT50) for the 59 of 149 individuals with NT50s 223 
>500 and individual 107. See also Extended Data Table 1. Asterisks indicate donors from which 224 
antibody sequences were derived. c, AUC for anti-RBD IgG ELISA (X axis) plotted against NT50 225 
(Y axis) r=0.6432, p=<0.0001. d, AUC for anti-S IgG ELISA (X axis) plotted against NT50 (Y 226 
axis) r=0.6721, p=<0.0001. e, NT50 for outpatients and hospitalized individuals p=0.0495. f, NT50 227 
for all males and females in the cohort p=0.0031. Dotted line in c to f (NT50=5) represents lower 228 
limit of detection (LLOD). Samples with undetectable neutralizing titers were plotted at LLOD. 229 
Correlations in c and d were determined by two-tailed Spearman’s. Statistical significance in e and 230 
f was determined using two-tailed Mann-Whitney U test. Horizontal bars indicate median values.   231 
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 232 
Figure 3. Anti-SARS-CoV-2 RBD antibodies. a. Representative flow cytometry plots showing 233 
dual AF647- and PE-RBD binding B cells in control and 6 study individuals (for gating strategy 234 
see Extended Data Fig. 6). Percentages of antigen specific B cells are indicated. Control is a 235 
healthy control sample obtained pre-COVID-19. b, Pie charts depicting the distribution of 236 
antibody sequences from 6 individuals. The number in the inner circle indicates the number of 237 
sequences analyzed for the individual denoted above the circle. White indicates sequences isolated 238 
only once, and grey or colored pie slices are proportional to the number of clonally related 239 
sequences. Red, blue, orange and yellow pie slices indicate clones that share the same IGHV and 240 
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IGLV genes. c, Circos plot shows sequences from all 6 individuals with clonal relationships 241 
depicted as in b. Interconnecting lines indicate the relationship between antibodies that share V 242 
and J gene segment sequences at both IGH and IGL. Purple, green and gray lines connect related 243 
clones, clones and singles, and singles to each other, respectively. d, Sample sequence alignment 244 
for antibodies originating from different individuals that display highly similar IGH V(D)J and 245 
IGL VJ sequences including CDR3s. Amino acid differences in CDR3s to the bolded reference 246 
sequence above are indicated in red and dots represent identities.  247 
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 248 
Figure 4. Anti-SARS-CoV-2 RBD antibody reactivity. a, Graph show results of ELISA assays 249 
measuring monoclonal antibody reactivity to RBD. Optical density units at 450 nm (OD, Y axis) 250 
vs. antibody concentrations (X axis). C121, C135 C144 and isotype control in red, green, purple, 251 
and black respectively, in all panels. b, Graph shows normalized relative luminescence values 252 
(RLU, Y axis) in cell lysates of 293TACE2 cells 48 hours after infection with SARS-CoV-2 253 
pseudovirus in the presence of increasing concentrations of monoclonal antibodies (X axis). c, 254 
RLU for SARS-CoV-2 pseudovirus assay (Y axis) vs. titration of monoclonal antibodies C121, 255 
C135 and C144 in one of two independent experiments (see Extended Data Table 6). d, SARS-256 
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CoV-2 real virus neutralization assay. Infected cells (Y axis) vs. titration of monoclonal antibodies 257 
C121, C135 and C144 in two independent experiments. For a and b panels, isotype control 258 
antibody in black. e, IC50s for antibodies assayed in b and d. f, Diagrammatic representation of 259 
biolayer interferometry experiment. g, Graph shows binding of C144, C101, C121, C009, C135, 260 
and CR302210,11 to RBD. h-m, Secondary antibody binding to preformed IgG-RBD complexes 261 
(Ab1). The table displays the shift in nanometers after second antibody (Ab2) binding to the 262 
antigen in the presence of the first antibody (Ab1). Values are normalized by the subtraction of the 263 
autologous antibody control.  o-q, Representative 2D-class averages and 3D reconstructed 264 
volumes for SARS-CoV-S 2P trimers complexed with C002, C119, and C121 Fabs. 2D-class 265 
averages with observable Fab density are boxed. r, Overlay of S-Fab complexes with fully-266 
occupied C002 (blue), C121 (magenta) and C119 (orange) Fabs aligned on the RBD “up” 267 
conformational state. The SARS-CoV-2 S model with 1 “up” RBD state (PDB 6VYB) was fit into 268 
the density and the SARS-CoV antibody S230 (PDB 6NB6) shown as reference (green ribbon).  269 
 270 
  271 
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Methods 272 
Study participants. Study participants were recruited at the Rockefeller University Hospital in 273 
New York from April 1 through May 8, 2020. Eligible participants were adults aged 18-76 years 274 
who were either diagnosed with SARS-CoV-2 infection by RT-PCR and were free of symptoms 275 
of COVID-19 for at least 14 days (cases), or who were close contacts (e.g., household, co-workers, 276 
members of same religious community) with someone who had been diagnosed with  SARS-CoV-277 
2 infection by RT-PCR and were free of symptoms suggestive of COVID-19 for at least 14 days 278 
(contacts). Exclusion criteria included presence of symptoms suggestive of active SARS-CoV-2 279 
infection, or hemoglobin < 12 g/dL for males and < 11 g/dL for females. 280 
Most study participants were residents of the Greater New York City tri-state region and were 281 
enrolled sequentially according to eligibility criteria. Participants were first interviewed by phone 282 
to collect information on their clinical presentation, and subsequently presented to the Rockefeller 283 
University Hospital for a single blood sample collection.  Participants were asked to rate the 284 
highest severity of their symptoms on a numeric rating scale ranging from 0 to 10. The score was 285 
adapted from the pain scale chart, where 0 was the lack of symptoms, 4 were distressing symptoms 286 
(e.g. fatigue, myalgia, fever, cough, shortness of breath) that interfered with daily living activities, 287 
7 were disabling symptoms that prevented the performance of daily living activities, and 10 was 288 
unimaginable/unspeakable discomfort (in this case, distress due to shortness of breath). All 289 
participants provided written informed consent before participation in the study and the study was 290 
conducted in accordance with Good Clinical Practice.  291 
 292 
Blood samples processing and storage. Peripheral Blood Mononuclear Cells (PBMCs) were 293 
obtained by gradient centrifugation and stored in liquid nitrogen in the presence of FCS and 294 
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DMSO. Heparinized plasma and serum samples were aliquoted and stored at -20°C or less. Prior 295 
to experiments, aliquots of plasma samples were heat-inactivated (56C for 1 hour) and then stored 296 
at 4C. 297 
 298 
Cloning, expression and purification of recombinant coronavirus proteins. Codon-optimized 299 
nucleotide sequences encoding the SARS-CoV-2 S ectodomain (residues 16-1206) and receptor 300 
binding domain (RBD; residues 331-524) were synthesized and subcloned into the mammalian 301 
expression pTwist-CMV BetaGlobin vector by Twist Bioscience Technologies based on an early 302 
SARS-CoV-2 sequence isolate (GenBank MN985325.1). The SARS-CoV-2 RBD construct 303 
included an N-terminal human IL-2 signal peptide and dual C-terminal tags ((GGGGS)2-304 
HHHHHHHH (octa-histidine), and GLNDIFEAQKIEWHE (AviTag)). In addition, the 305 
corresponding S1B or receptor binding domains for SARS-CoV S (residues 318-510; GenBank 306 
AAP13441.1), MERS-CoV S (residues 367-588; GenBank JX869059.2), HCoV-NL63 (residues 307 
481-614; GenBank AAS58177.1), HCoV-OC43 (residues 324-632; GenBank AAT84362.1), and 308 
HCoV-229E (residues 286-434; GenBank AAK32191.1) were synthesized with the same N- and 309 
C-terminal extensions as the SARS-CoV-2 RBD construct and subcloned into the mammalian 310 
expression pTwist-CMV BetaGlobin vector (Twist Bioscience Technologies).  The SARS-CoV-2 311 
S ectodomain was modified as previously described 4. Briefly, the S ectodomain construct included 312 
an N-terminal mu-phosphatase signal peptide, 2P stabilizing mutations (K986P and V987P), 313 
mutations to remove the S1/S2 furin cleavage site (682RRAR685 to GSAS), a C-terminal extension 314 
(IKGSG-RENLYFQG (TEV protease site), GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL 315 
(foldon trimerization motif), G-HHHHHHHH (octa-histidine tag), and GLNDIFEAQKIEWHE 316 
(AviTag)). The SARS-CoV-2 S 2P ectodomain and RBD constructs were produced by transient 317 
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transfection of 500 mL of Expi293 cells (Thermo Fisher) and purified from clarified transfected 318 
cell supernatants four days post-transfection using Ni2+-NTA affinity chromatography (GE Life 319 
Sciences). Affinity-purified proteins were concentrated and further purified by size-exclusion 320 
chromatography (SEC) using a Superdex200 16/60 column (GE Life Sciences) running in 1x TBS 321 
(20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.02% NaN3). Peak fractions were analyzed by SDS- 322 
PAGE, and fractions corresponding to soluble S 2P trimers or monomeric RBD proteins were 323 
pooled and stored at 4˚C.  324 
 325 
ELISAs. ELISAs to evaluate antibodies binding to SARS-CoV-2 RBD and trimeric spike proteins 326 
were performed by coating of high binding 96 half well plates (Corning #3690) with 50 µL per 327 
well of a 1µg/mL protein solution in PBS overnight at 4°C. Plates were washed 6 times with 328 
washing buffer (1xPBS with 0.05% Tween 20 (Sigma-Aldrich)) and incubated with 170 µL per 329 
well blocking buffer (1xPBS with 2% BSA and 0.05% Tween20 (Sigma)) for 1 hour at room 330 
temperature (RT). Immediately after blocking, monoclonal antibodies or plasma samples were 331 
added in PBS and incubated for 1 hr at RT. Plasma samples were assayed at a 1:200 starting 332 
dilution and seven additional 3-fold serial dilutions. Monoclonal antibodies were tested at 10µg/ml 333 
starting concentration and 10 additional 4-fold serial dilutions. Plates were washed 6 times with 334 
washing buffer and then incubated with anti-human IgG or IgM secondary antibody conjugated to 335 
horseradish peroxidase (HRP) (Jackson Immuno Research 109-036-088 and 109-035-129) in 336 
blocking buffer at a 1:5000 dilution. Plates were developed by addition of the HRP substrate, TMB 337 
(ThermoFisher) for 10 minutes, then the developing reaction was stopped by adding 50µl 1M 338 
H2SO4 and absorbance was measured at 450nm with an ELISA microplate reader (FluoStar 339 
Omega, BMG Labtech). For plasma samples, a positive control (plasma from patient COV21, 340 
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diluted 200-fold in PBS) was added in duplicate to every assay plate. The average of its signal was 341 
used for normalization of all the other values on the same plate with Excel software prior to 342 
calculating the area under the curve using Prism 8 (GraphPad). For monoclonal antibodies, the 343 
half-maximal effective concentration (EC50) was determined using 4-parameter nonlinear 344 
regression (GraphPad Prism). 345 
 346 
293TACE2 cells. For constitutive expression of ACE2 in 293T cells, a cDNA encoding ACE2, 347 
carrying two inactivating mutations in the catalytic site (H374N & H378N), was inserted into CSIB 348 
3’ to the SFFV promoter25. 293TACE2 cells were generated by transduction with CSIB based virus 349 
followed by selection with 5 µg/ml Blasticidin.  350 
 351 
SARS-CoV-2 and SARS-CoV pseudotyped reporter viruses. A plasmid expressing a C-352 
terminally truncated SARS-CoV-2 S protein (pSARS-CoV2-Strunc) was generated by insertion of 353 
a human-codon optimized cDNA encoding SARS-CoV-2 S lacking the C-terminal 19 codons 354 
(Geneart) into pCR3.1. The S ORF was taken from “Wuhan seafood market pneumonia virus 355 
isolate Wuhan-Hu-1” (NC_045512). For expression of full-length SARS-CoV S protein, “Human 356 
SARS coronavirus Spike glycoprotein Gene ORF cDNA clone expression plasmid (Codon 357 
Optimized)” (here referred to as pSARS-CoV-S) was obtained from SinoBiological (Cat: 358 
VG40150-G-N). An env-inactivated HIV-1 reporter construct (pNL4-3DEnv-nanoluc) was 359 
generated from pNL4-326 by introducing a 940 bp deletion 3’ to the vpu stop-codon, resulting in a 360 
frameshift in env. The human codon-optimized nanoluc Luciferase reporter gene (Nluc, Promega) 361 
was inserted in place of nucleotides 1-100 of the nef-gene. To generate pseudotyped viral stocks, 362 
293T cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV2-Strunc or pSARS-CoV-363 
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S using polyethyleneimine. Co-transfection of pNL4-3DEnv-nanoluc and S-expression plasmids 364 
leads to production of HIV-1-based virions carrying either the SARS-CoV-2 or SARS-CoV spike 365 
protein on the surface. Eight hours after transfection, cells were washed twice with PBS and fresh 366 
media was added. Supernatants containing virions were harvested 48 hours post transfection, 367 
filtered and stored at -80°C. Infectivity of virions was determined by titration on 293TACE2 cells.  368 
 369 
Pseudotyped virus neutralization assay. Five-fold serially diluted plasma from COVID-19 370 
convalescent individuals and healthy donors or four-fold serially diluted monoclonal antibodies 371 
were incubated with the SARS-CoV-2 or SARS-CoV pseudotyped virus for 1 hour at 37°C 372 
degrees. The mixture was subsequently incubated with 293TACE2 cells for 48 hours after which 373 
cells were washed twice with PBS and lysed with Luciferase Cell Culture Lysis 5x reagent 374 
(Promega). Nanoluc Luciferase activity in lysates was measured using the Nano-Glo Luciferase 375 
Assay System (Promega). Relative luminescence units obtained were normalized to those derived 376 
from cells infected with SARS-CoV-2 or SARS-CoV pseudotyped virus in the absence of plasma 377 
or monoclonal antibodies. The half-maximal inhibitory concentration for plasma (NT50) or 378 
monoclonal antibodies (IC50) was determined using 4-parameter nonlinear regression (GraphPad 379 
Prism).  380 
Cell lines, virus and virus titration. VeroE6 kidney epithelial cells (Chlorocebus sabaeus) and 381 
Huh-7.5 hepatoma cells (H. sapiens) were cultured in Dulbecco’s Modified Eagle Medium 382 
(DMEM) supplemented with 1% nonessential amino acids (NEAA) and 10% fetal bovine serum 383 
(FBS) at 37oC and 5% CO2. All cell lines have been tested negative for contamination with 384 
mycoplasma and were obtained from the ATCC (with the exception for Huh-7.5). 385 
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SARS-CoV-2, strain USA-WA1/2020, was obtained from BEI Resources and amplified in VeroE6 386 
cells at 33°C. Viral titers were measured on Huh-7.5 cells by standard plaque assay (PA). Briefly, 387 
500 µL of serial 10-fold virus dilutions in Opti-MEM were used to infect 400,000 cells seeded the 388 
day prior in a 6-well plate format. After 90 min adsorption, the virus inoculum was removed, and 389 
cells were overlayed with DMEM containing 10% FBS with 1.2% microcrystalline cellulose 390 
(Avicel). Cells were incubated for five days at 33°C, followed by fixation with 3.5% formaldehyde 391 
and crystal violet staining for plaque enumeration. All experiments were performed in a biosafety 392 
level 3 laboratory.  393 
Microscopy-based neutralization assay of authentic SARS-CoV-2. The day prior to infection 394 
VeroE6 cells were seeded at 12,500 cells/well into 96-well plates. Antibodies were serially diluted 395 
in BA-1, mixed with a constant amount of SARS-CoV-2 (grown in VeroE6) and incubated for 60 396 
min at 37°C. The antibody-virus-mix was then directly applied to VeroE6 cells (MOI of ~0.1 397 
PFU/cell). Cells were fixed 18 hours post infection by adding an equal volume of 7% formaldehyde 398 
to the wells, followed by permeabilization with 0.1% Triton X-100 for 10 min. After extensive 399 
washing, cells were incubated for 1 hour at room temperature with blocking solution of 5% goat 400 
serum in PBS (catalog no. 005–000-121; Jackson ImmunoResearch). A rabbit polyclonal anti-401 
SARS-CoV-2 nucleocapsid antibody (catalog no. GTX135357; GeneTex) was added to the cells 402 
at 1:500 dilution in blocking solution and incubated at 4°C overnight. A goat anti-rabbit 403 
AlexaFluor 594 (catalog no. A-11012; Life Technologies) at a dilution of 1:2,000 was used as a 404 
secondary antibody. Nuclei were stained with Hoechst 33342 (catalog no. 62249; Thermo 405 
Scientific) at a 1:1,000 dilution. Images were acquired with a fluorescence microscope and 406 
analyzed using ImageXpress Micro XLS (Molecular Devices, Sunnyvale, CA). All statistical 407 
analyses were done using Prism 8 software (GraphPad). 408 
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Biotinylation of viral protein for use in flow cytometry. Purified and Avi-tagged SARS-CoV-2 409 
RBD was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer’s 410 
instructions (Avidity). Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-411 
NHS-LC-Biotinylation kit according to the manufacturer’s instructions (Thermo Scientific). 412 
Biotinylated Ovalbumin was conjugated to streptavidin-BV711 (BD biosciences, 563262) and 413 
RBD to streptavidin-PE (BD biosciences, 554061) and streptavidin-Alexa Fluor 647 (AF647, 414 
Biolegend, 405237) respectively27. 415 
 416 
Single cell sorting by flow cytometry. PBMCs were enriched for B cells by negative selection 417 
using a pan B cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, 130-418 
101-638). The enriched B cells were incubated in FACS buffer (1 X Phosphate-buffered Saline 419 
(PBS), 2% calf serum, 1 mM EDTA) with the following anti-human antibodies: anti-CD20-PECy7 420 
(BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-421 
eFluro 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluro 780 (Invitrogen, 47-0168-41), anti-422 
CD14-APC-eFluro 780 (Invitrogen, 47-0149-42), as well as Zombie NIR (BioLegend, 423105), 423 
and fluorophore-labeled RBD and Ovalbumin for 30 minutes on ice27. Single CD3-CD8-CD16-424 
CD20+Ova-RBD-PE+RBD-AF647+ B cells were sorted into individual wells of a 96-well plates 425 
containing 4 μl of lysis buffer (0.5 X PBS, 10mM DTT, 3000 units/mL RNasin Ribonuclease 426 
Inhibitors (Promega, N2615) per well using a FACS Aria III (Becton Dickinson). The sorted cells 427 
were frozen on dry ice, and then stored at −80°C or immediately used for subsequent RNA reverse 428 
transcription. Although cells were not stained for IgG expression, they are memory B cells based 429 
on the fact that they are CD20+ (a marker absent in plasmablasts) and they express IgG (since 430 
antibodies were amplified from these cells using IgG-specific primers). 431 
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 432 
Antibody sequencing, cloning and expression. Antibodies were identified and sequenced as 433 
described previously22,28,29. Briefly, RNA from single cells was reverse-transcribed (SuperScript 434 
III Reverse Transcriptase, Invitrogen, 18080-044) and the cDNA stored at -20°C or used for 435 
subsequent amplification of the variable IGH, IGL and IGK genes by nested PCR and Sanger 436 
sequencing28. Amplicons from the first PCR reaction were used as templates for Sequence- and 437 
Ligation-Independent Cloning (SLIC) into antibody expression vectors. Recombinant monoclonal 438 
antibodies and Fabs were produced and purified as previously described30,31.  439 
 440 
Biolayer interferometry. 441 
BLI assays were performed on the Octet Red instrument (ForteBio) at 30°C with shaking at 1,000 442 
r.p.m. Epitope binding assays were performed with protein A biosensor (ForteBio 18-5010), 443 
following the manufacture protocol “classical sandwich assay”. (1) Sensor check: sensors 444 
immersed 30 sec in buffer alone (buffer ForteBio 18-1105). (2) Capture 1st Ab: sensors immersed 445 
10min with Ab1 at 40 µg/mL. (3) Baseline: sensors immersed 30sec in buffer alone. (4) Blocking: 446 
sensors immersed 5 min with IgG isotype control at 50 µg/mL. (6) Antigen association: sensors 447 
immersed 5 min with RBD at 100 µg/mL. (7) Baseline: sensors immersed 30 sec in buffer alone. 448 
(8) Association Ab2: sensors immersed 5min with Ab2 at 40 µg/mL. Curve fitting was performed 449 
using the Data analysis software (ForteBio). 450 
  451 
Computational analyses of antibody sequences. Antibody sequences were trimmed based on 452 
quality and annotated using Igblastn v1.14.032 with IMGT domain delineation system. Annotation 453 
was performed systematically using Change-O toolkit v.0.4.533.  Heavy and light chains derived 454 
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from the same cell were paired, and clonotypes were assigned based on their V and J genes using 455 
in-house R and Perl scripts (Fig. 3 b,c). All scripts and the data used to process antibody sequences 456 
are publicly available on GitHub (https://github.com/stratust/igpipeline). 457 
The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 458 
was compared to Sequence Read Archive SRP01097034. The V(D)J assignments were done using 459 
IMGT/High V-Quest and the frequencies of heavy and light chain V genes were calculated for 14 460 
and 13 individuals, respectively, using sequences with unique CDR3s. The two-tailed t test with 461 
unequal variances was used to determine statistical significance (Extended Data Fig. 7). 462 
Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl 463 
scripts. For somatic hypermutations, IGHV and IGLV nucleotide sequences were aligned against 464 
their closest germlines using IgBlast and the number of differences were considered nucleotide 465 
mutations. The average mutations for V genes was calculated by dividing the sum of all nucleotide 466 
mutations across all patients by the number of sequences used for the analysis. To calculate the 467 
GRAVY scores of hydrophobicity35 we used Guy H.R. Hydrophobicity scale based on free energy 468 
of transfer (kcal/mole)36 implemented by the R package Peptides available in the Comprehensive 469 
R Archive Network repository (https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-2015-470 
001.pdf). We used 534 heavy chain CDR3 amino acid sequences from this study and 22,654,256 471 
IGH CDR3 sequences from the public database of memory B-cell receptor sequences37. The 472 
Shapiro-Wilk test was used to determine whether the GRAVY scores are normally distributed. 473 
The GRAVY scores from all 533 IGH CDR3 amino acid sequences from this study 474 
(sequence COV047_P4_IgG_51-P1369 lacks CDR3 amino acid sequence) were used to perform 475 
the test and 5000 GRAVY scores of the sequences from the public database were randomly 476 
selected. The Shapiro-Wilk p-values were 6.896 x 10-3 and 2.217 x 10-6 for sequences from this 477 
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study and the public database, respectively, indicating the data are not normally distributed. 478 
Therefore, we used the Wilcoxon non-parametric test to compare the samples, which indicated a 479 
difference in hydrophobicity distribution (p = 5 x 10-6; Extended Data Fig. 8). 480 
 481 
Negative-stain EM Data Collection and Processing 482 
Purified Fabs (C002, C119, and C121) were complexed with SARS-CoV-2 S trimer at a 2-fold 483 
molar excess for 1 min and diluted to 40 µg/mL in TBS immediately before adding 3 µL to a 484 
freshly-glow discharged ultrathin, 400 mesh carbon-coated copper grid (Ted Pella, Inc.). Samples 485 
were blotted after a 1 min incubation period and stained with 1% uranyl formate for an additional 486 
minute before imaging. Micrographs were recorded on a Thermo Fisher Talos Arctica transmission 487 
electron microscope operating at 200 keV using a K3 direct electron detector (Gatan, Inc) and 488 
SerialEM automated image acquisition software38. Images were acquired at a nominal 489 
magnification of 28,000x (1.44 Å/pixel size) and a -1.5 to -2.0 µm defocus range. Images were 490 
processed in cryoSPARC v2.14, and reference-free particle picking was completed using a 491 
gaussian blob picker39. Reference-free 2D class averages and ab initio volumes were generated in 492 
cryoSPARC, and subsequently 3D-classified to identify classes of S-Fab complexes, that were 493 
then homogenously refined. Figures were prepared using UCSF Chimera40. 494 
  495 
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Extended Data Tables 525 
 526 
   
Extended Data Table 1. Individual participant demographics and clinical characteristics
ID Age Gender Race IgG IgM IgG IgM
5 43 M White Non-Hispanic Case 9 41 9 2.52 2.35 5.51 2.43 5.0
7 40 M White Non-Hispanic Case 11 30 6 2.92 2.54 7.39 2.37 2730.4
8 37 M White Non-Hispanic Case 3 57 5 2.11 0.81 4.46 0.88 5.0
9 35 F White Non-Hispanic Case 12 54 5 2.90 1.07 4.44 2.80 5.0
12 27 F White Non-Hispanic Contact 7 24 3 1.47 1.71 4.31 1.23 5.0
13 28 M White Non-Hispanic Case 5 25 3 1.97 4.10 3.95 1.38 173.2
18 55 M White Non-Hispanic Case 16 28 6 2.57 1.75 3.92 1.31 410.3
20 26 F White Non-Hispanic Case 2 17 5 1.80 2.00 4.49 1.68 5.0
21 54 M White Hispanic Contact 11 27 7 5.60 2.88 7.60 2.47 5052.7
24 34 M White Non-Hispanic Case 15 30 4 2.29 1.97 4.36 1.45 280.7
26 66 M White Non-Hispanic Case 2 35 3 1.67 1.86 4.00 1.58 276.1
27 28 M White Non-Hispanic Case 9 32 4 1.79 1.64 4.41 1.30 739.3
28 26 M White Non-Hispanic Case 7 21 4 2.39 2.25 4.93 1.66 888.9
29 26 F White Non-Hispanic Contact 5 35 4 1.69 1.54 3.93 1.97 5.0
30 30 M White Non-Hispanic Contact 3 35 4 3.07 2.55 4.86 1.34 5.0
31 51 M White Non-Hispanic Case 9 33 3 1.29 1.60 4.69 1.20 192.3
32 46 F White Non-Hispanic Case 8 32 3 1.30 2.18 3.79 0.83 47.4
37 27 M White Non-Hispanic Case 6 28 6 2.13 1.52 4.11 1.04 286.3
38 57 F White Non-Hispanic Case 10 38 4 1.87 2.02 4.30 1.12 518.9
40 44 M White Non-Hispanic Case 7 23 5 1.72 1.50 3.81 1.47 42.1
41 35 M White Non-Hispanic Contact 10 29 8 2.13 1.67 4.15 0.98 302.5
42 40 M White Non-Hispanic Contact 20 36 8 2.37 1.50 5.82 1.43 627.1
45 55 F White Non-Hispanic Case 7 48 6 1.95 0.97 3.53 0.75 5.0
46 39 M White Non-Hispanic Case 8 30 2 2.68 1.45 4.14 1.29 59.2
47 43 F White Non-Hispanic Case 11 33 5 3.02 2.30 6.23 2.66 10433.3
48 37 F White Non-Hispanic Case 7 21 5 1.51 1.85 3.47 1.51 173.4
50 27 F White Non-Hispanic Contact 7 28 4 1.64 2.32 5.42 1.45 924.7
51 21 M White Non-Hispanic Contact 8 31 5 1.76 1.69 3.94 1.03 1499.2
54 40 F White Non-Hispanic Contact 3 24 3 1.80 2.10 4.99 1.42 5.0
55 36 M White Non-Hispanic Case 3 49 2 1.43 1.23 3.90 2.09 5.0
56 75 F White Non-Hispanic Case 22 40 3 1.79 1.81 5.89 1.47 1388.4
57 66 M White Non-Hispanic Case 6 21 5 1.54 2.10 4.33 1.00 2048.9
58 64 F White Non-Hispanic Contact 1 32 2 1.20 1.71 3.95 1.21 5.0
64 28 F White Non-Hispanic Contact 11 32 6 2.36 2.06 4.48 1.66 776.7
67 19 F N/A Hispanic Case 5 29 6 2.56 1.98 5.48 1.32 2052.9
71 45 F White Non-Hispanic Case 12 48 7 1.55 2.04 3.86 1.53 33.3
72 42 M White Non-Hispanic Case 16 35 8 4.05 3.58 6.05 2.59 3138.2
75 46 F White Non-Hispanic Case 10 36 4 1.64 2.37 3.98 1.20 271.5
76 49 F White Non-Hispanic Case 28 34 4 1.88 1.65 5.17 0.97 219.8
77 37 M White Non-Hispanic Contact 6 33 4 1.33 1.83 3.56 1.16 5.0
81 44 F White Non-Hispanic Contact 3 35 2 1.58 1.73 3.82 1.10 5.0
82 46 M N/A Non-Hispanic Case 0 0 2.19 1.92 5.41 1.81 130.7
88 41 M White Non-Hispanic Case 7 23 4 1.82 3.32 4.97 1.37 424.7
95 44 M White Non-Hispanic Case 9 36 6 2.61 1.62 6.03 1.62 961.9
96 48 F White Non-Hispanic Case 9 30 3 3.93 1.93 6.25 2.26 927.7
97 39 M White Non-Hispanic Case 9 31 3 1.58 1.61 4.03 2.33 202.7
98 35 F White Non-Hispanic Case 2 24 4 1.78 1.47 5.38 1.22 249.0
99 36 F White Non-Hispanic Case 13 29 5 2.50 3.27 4.38 2.49 1127.6
107 53 F White Non-Hispanic Contact 10 29 4 1.74 1.41 4.66 0.90 297.5
108 75 M White Non-Hispanic Case 16 41 7 1.37 0.88 3.47 1.36 557.5
110 27 M White Non-Hispanic Case 1 25 1 1.30 1.60 4.00 0.93 5.0
114 30 F White Non-Hispanic Case 15 36 7 1.65 1.92 3.53 1.55 110.9
115 65 F White Non-Hispanic Contact 20 41 6 2.10 3.28 4.32 3.27 1127.7
119 56 M White Non-Hispanic Case 13 48 3 1.36 1.26 4.41 1.59 650.3
120 56 F White Non-Hispanic Case 26 48 6 0.99 0.97 3.65 1.21 100.6
121 19 M White Non-Hispanic Contact 3 42 2 0.85 0.87 3.56 1.26 5.0
122 21 F White Non-Hispanic Contact 3 38 1 1.44 0.94 3.39 1.22 5.0
123 26 M White Non-Hispanic Contact 12 34 6 0.94 0.95 3.39 1.40 5.0
124 63 F Asian Non-Hispanic Contact 4 37 3 1.58 2.06 3.49 1.32 5.0
125 51 F White Non-Hispanic Case 10 26 3 1.92 3.49 3.86 1.24 126.5
127 24 F White Non-Hispanic Case 10 43 6 1.80 2.50 4.37 2.41 883.5
130 39 M White Non-Hispanic Contact 7 28 5 1.24 1.72 3.91 1.34 5.0
131 39 M White Non-Hispanic Case 5 25 4 1.46 1.38 4.44 1.03 7.8
132 36 M White Non-Hispanic Contact 10 50 6 2.15 1.76 4.84 1.97 5.0
134 27 F White Non-Hispanic Contact 16 22 5 2.51 2.18 6.84 1.94 2700.6
135 62 F White Non-Hispanic Case 8 31 6 2.20 2.02 3.80 1.13 350.0
140 63 F White Non-Hispanic Case 28 47 1 1.05 1.24 3.58 1.28 52.4
149 41 M White Non-Hispanic Contact 17 28 6 1.68 2.02 3.67 1.09 494.9
150 50 F White Non-Hispanic Contact 12 45 7 1.15 0.43 3.18 1.82 5.0
154 68 M Asian Non-Hispanic Case 16 30 9 3.19 2.19 4.85 1.29 928.2
157 50 M White Non-Hispanic Case 10 32 8 2.40 2.86 3.90 2.06 741.7
166 28 F White Non-Hispanic Case 13 45 2 1.27 0.66 3.45 0.94 5.0
167 50 F White Non-Hispanic Contact 11 41 6 1.43 3.71 3.93 8.74 5.0
172 38 F White Non-Hispanic Case 8 22 9 1.71 2.58 4.29 1.20 301.1
173 47 M White Non-Hispanic Case 5 47 7 2.57 4.14 4.78 4.48 646.9
178 26 F White Non-Hispanic Case 6 24 4 1.54 1.59 3.66 1.02 5.0
179 39 M White Non-Hispanic Contact 10 37 3 1.89 2.25 3.83 1.73 370.1
182 44 F White Non-Hispanic Contact 10 38 6 3.80 1.77 5.36 8.05 1503.7
183 43 F White Non-Hispanic Case 13 44 8 1.56 1.02 3.88 1.55 240.1
185 54 M White Non-Hispanic Case 11 44 8 3.51 1.39 5.55 2.11 1806.8
186 38 F N/A N/A Case 8 26 2 1.73 2.47 4.37 1.23 296.9
190 54 F White Non-Hispanic Case 18* 63 9 3.24 1.24 7.38 1.42 598.1
195 24 M White Non-Hispanic Case 18 42 5 2.74 2.55 5.01 2.33 1315.1
200 60 F White Non-Hispanic Case 17 39 7 2.40 1.00 4.38 1.51 1014.4
201 50 M White Non-Hispanic Contact 15 33 6 4.37 2.57 6.15 1.57 3897.4
202 57 M White Non-Hispanic Case 21 34 7 2.10 2.08 5.07 1.17 257.9
205 64 M White Non-Hispanic Case 7 36 4 4.51 0.70 6.12 1.69 924.4
222 28 M Asian Non-Hispanic Case 11 29 7 1.28 0.69 3.94 3.46 5.0
229 45 M White Non-Hispanic Case 10 63 4 2.92 1.42 4.90 1.58 1272.9
230 50 M White Non-Hispanic Case 18 33 7 3.80 0.47 3.48 0.88 5.0
232 38 F White Non-Hispanic Case 13 43 7 1.57 0.70 4.24 5.70 94.3
233 55 M White Non-Hispanic Case 20 41 3 2.07 2.11 4.51 1.07 173.2
241 36 M White Non-Hispanic Case 12 30 7 2.27 2.66 4.54 1.46 923.1
242 59 M White Non-Hispanic Case 10 42 6 4.91 1.94 4.81 2.16 1353.0
243 30 F Asian Non-Hispanic Case 6 26 5 2.92 2.57 5.06 1.14 1300.2
246 44 F White Non-Hispanic Case 10 38 7 2.05 2.79 6.09 1.32 566.0
255 33 M White Non-Hispanic Case 14 44 6 2.14 0.70 4.20 1.24 172.5
256 63 F White Non-Hispanic Case 27 42 6 1.72 1.96 4.26 7.79 141.6
258 52 M White Non-Hispanic Contact 14 48 6 2.64 1.20 4.52 1.85 4145.9
279 41 M White Non-Hispanic Case 7 38 8 1.68 2.13 3.77 1.90 308.9
280 59 M White Non-Hispanic Case 6 32 7 2.53 3.07 4.61 1.19 1072.1
302 47 F White Non-Hispanic Case 35* 49 7 1.48 0.97 4.06 1.26 5.0
310 34 F White Non-Hispanic Case 17 35 5 3.95 1.24 9.44 3.07 485.5
314 46 M White Non-Hispanic Case 11 38 7 2.12 0.88 4.56 1.51 667.1
315 29 F White Non-Hispanic Case 15 42 8 3.02 0.69 3.98 1.03 376.5
319 50 M White Non-Hispanic Case 5 38 6 3.71 2.28 3.79 1.05 5.0
323 39 F White Non-Hispanic Case 7 45 7 1.05 1.03 3.53 1.42 5.0
325 52 M White Non-Hispanic Case 16 38 8 2.25 1.47 4.83 2.28 1603.3
343 21 F White Non-Hispanic Case 16 49 5 1.63 0.94 3.37 1.70 5.0
352 44 M White Non-Hispanic Case 16 43 4 3.54 0.92 4.50 1.07 519.2
353 60 M White Non-Hispanic Case 14 49 6 5.38 1.12 5.69 1.05 855.5
356 22 F White Non-Hispanic Contact 16 38 3 1.37 0.61 2.98 1.09 5.0
357 27 F White Non-Hispanic Contact 34 56 5 7.49 1.10 2.77 1.13 5.0
364 29 M White Non-Hispanic Contact 14 49 6 0.97 0.58 2.90 0.89 5.0
366 41 F White Non-Hispanic Contact 9 34 7 0.98 0.52 3.51 1.19 5.0
373 35 F White Non-Hispanic Case 12 51 7 1.69 1.26 5.14 1.69 5.0
388 47 F White Non-Hispanic Contact 14 41 9 1.57 1.06 3.61 1.69 5.0
393 69 M White Non-Hispanic Case 23* 54 9 1.28 1.74 3.81 2.65 715.4
394 48 F Multiple Hispanic Case 7 67 4 2.05 0.87 4.34 2.02 1281.5
397 52 M White Non-Hispanic Case 22 45 8 3.32 0.59 5.01 0.87 1516.9
403 52 M Asian Non-Hispanic Case 18* 39 10 5.36 1.09 10.01 1.36 3887.8
406 65 M White Non-Hispanic Case 20 56 8 4.69 0.90 7.51 1.15 1288.7
410 34 M White Non-Hispanic Case 12 46 8 1.06 0.56 3.95 0.76 5.0
421 62 F White Non-Hispanic Contact 12 43 9 0.95 1.07 3.34 1.35 5.0
426 65 M White Non-Hispanic Case 18 51 6 2.07 0.55 3.95 1.49 804.8
437 43 F Asian Non-Hispanic Case 14 34 7 2.54 0.47 4.30 1.44 698.8
460 36 M White Non-Hispanic Case 11 39 6 2.94 3.18 5.51 2.80 1906.7
461 49 M White Non-Hispanic Case 7 39 5 3.38 0.94 4.67 2.02 1076.6
462 28 F White Non-Hispanic Case 16 45 5 1.36 0.38 3.07 1.11 5.0
470 28 F White Non-Hispanic Case 17 51 4 1.26 0.86 3.97 1.50 5.0
478 31 M White Non-Hispanic Case 16 52 4 1.43 0.93 3.70 1.97 263.2
481 28 F Asian Non-Hispanic Case 15 43 8 1.70 0.39 3.46 1.24 5.0
486 64 F White Non-Hispanic Case 11 41 10 1.70 1.00 3.68 1.29 5.0
500 46 M White Non-Hispanic Case 12 53 5 1.10 0.82 3.49 1.34 5.0
501 32 M Asian Non-Hispanic Case 18* 53 10 2.62 0.65 4.51 1.21 718.8
502 52 M White Non-Hispanic Case 16* 53 9 5.10 0.61 5.10 1.62 2171.8
506 46 M White Non-Hispanic Case 12 59 9 0.84 0.81 3.13 1.21 5.0
507 39 M White Non-Hispanic Case 15 60 8 1.92 0.96 4.56 1.52 5.0
509 36 M White Non-Hispanic Case 11 50 5 1.99 1.01 3.99 1.45 5.0
526 49 M Asian Non-Hispanic Case 11 34 7 3.36 1.45 5.88 1.57 4193.3
537 52 M White Non-Hispanic Case 15 45 6 1.47 0.95 3.65 1.58 923.3
539 73 F White Non-Hispanic Case 19* 54 10 2.82 0.63 4.46 1.45 487.9
547 59 M White Non-Hispanic Case 15* 36 9 2.97 1.53 5.08 2.59 2900.6
587 54 M PI N/A Case 17* 51 8 3.22 0.60 4.01 1.49 473.1
632 38 M White Non-Hispanic Contact 10 43 6 2.49 0.86 4.50 1.63 572.3
633 39 M White Non-Hispanic Contact 8 57 4 1.25 1.04 3.38 1.73 5.0
652 76 M White Non-Hispanic Case 18* 56 10 4.75 1.46 8.96 3.80 2324.0
664 45 F White Non-Hispanic Case 17* 42 10 1.68 0.43 3.93 1.32 5.0
675 47 M White Non-Hispanic Contact 31 47 5 0.79 0.93 2.94 1.38 5.0
*hospitalized, Sx=symptoms
Case/ContactEthnicity
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Extended Data Table 1. Individual participant demographics and clinical characteristics
ID Age Gender Race IgG IgM IgG IgM
5 43 M White Non-Hispanic Case 9 41 9 2.52 2.35 5.51 2.43 5.0
7 40 M White Non-Hispanic Case 11 30 6 2.92 2.54 7.39 2.37 2730.4
8 37 M White Non-Hispanic Case 3 57 5 2.11 0.81 4.46 0.88 5.0
9 35 F White Non-Hispanic Case 12 54 5 2.90 1.07 4.44 2.80 5.0
12 27 F White Non-Hispanic Contact 7 24 3 1.47 1.71 4.31 1.23 5.0
13 28 M White Non-Hispanic Case 5 25 3 1.97 4.10 3.95 1.38 173.2
18 55 M White Non-Hispanic Case 16 28 6 2.57 1.75 3.92 1.31 410.3
20 26 F White Non-Hispanic Case 2 17 5 1.80 2.00 4.49 1.68 5.0
21 54 M White Hispanic Contact 11 27 7 5.60 2.88 7.60 2.47 5052.7
24 34 M White Non-Hispanic Case 15 30 4 2.29 1.97 4.36 1.45 280.7
26 66 M White Non-Hispanic Case 2 35 3 1.67 1.86 4.00 1.58 276.1
27 28 M White Non-Hispanic Case 9 32 4 1.79 1.64 4.41 1.30 739.3
28 26 M White Non-Hispanic Case 7 21 4 2.39 2.25 4.93 1.66 888.9
29 26 F White Non-Hispanic Contact 5 35 4 1.69 1.54 3.93 1.97 5.0
30 30 M White Non-Hispanic Contact 3 35 4 3.07 2.55 4.86 1.34 5.0
31 51 M White Non-Hispanic Case 9 33 3 1.29 1.60 4.69 1.20 192.3
32 46 F White Non-Hispanic Case 8 32 3 1.30 2.18 3.79 0.83 47.4
37 27 M White Non-Hispanic Case 6 28 6 2.13 1.52 4.11 1.04 286.3
38 57 F White Non-Hispanic Case 10 38 4 1.87 2.02 4.30 1.12 518.9
40 44 M White Non-Hispanic Case 7 23 5 1.72 1.50 3.81 1.47 42.1
41 35 M White Non-Hispanic Contact 10 29 8 2.13 1.67 4.15 0.98 302.5
42 40 M White Non-Hispanic Contact 20 36 8 2.37 1.50 5.82 1.43 627.1
45 55 F White Non-Hispanic Case 7 48 6 1.95 0.97 3.53 0.75 5.0
46 39 M White Non-Hispanic Case 8 30 2 2.68 1.45 4.14 1.29 59.2
47 43 F White Non-Hispanic Case 11 33 5 3.02 2.30 6.23 2.66 10433.3
48 37 F White Non-Hispanic Case 7 21 5 1.51 1.85 3.47 1.51 173.4
50 27 F White Non-Hispanic Contact 7 28 4 1.64 2.32 5.42 1.45 924.7
51 21 M White Non-Hispanic Contact 8 31 5 1.76 1.69 3.94 1.03 1499.2
54 40 F White Non-Hispanic Contact 3 24 3 1.80 2.10 4.99 1.42 5.0
55 36 M White Non-Hispanic Case 3 49 2 1.43 1.23 3.90 2.09 5.0
56 75 F White Non-Hispanic Case 22 40 3 1.79 1.81 5.89 1.47 1388.4
57 66 M White Non-Hispanic Case 6 21 5 1.54 2.10 4.33 1.00 2048.9
58 64 F White Non-Hispanic Contact 1 32 2 1.20 1.71 3.95 1.21 5.0
64 28 F White Non-Hispanic Contact 11 32 6 2.36 2.06 4.48 1.66 776.7
67 19 F N/A Hispanic Case 5 29 6 2.56 1.98 5.48 1.32 2052.9
71 45 F White Non-Hispanic Case 12 48 7 1.55 2.04 3.86 1.53 33.3
72 42 M White Non-Hispanic Case 16 35 8 4.05 3.58 6.05 2.59 3138.2
75 46 F White Non-Hispanic Case 10 36 4 1.64 2.37 3.98 1.20 271.5
76 49 F White Non-Hispanic Case 28 34 4 1.88 1.65 5.17 0.97 219.8
77 37 M White Non-Hispanic Contact 6 33 4 1.33 1.83 3.56 1.16 5.0
81 44 F White Non-Hispanic Contact 3 35 2 1.58 1.73 3.82 1.10 5.0
82 46 M N/A Non-Hispanic Case 0 0 2.19 1.92 5.41 1.81 130.7
88 41 M White Non-Hispanic Case 7 23 4 1.82 3.32 4.97 1.37 424.7
95 44 M White Non-Hispanic Case 9 36 6 2.61 1.62 6.03 1.62 961.9
96 48 F White Non-Hispanic Case 9 30 3 3.93 1.93 6.25 2.26 927.7
97 39 M White Non-Hispanic Case 9 31 3 1.58 1.61 4.03 2.33 202.7
98 35 F White Non-Hispanic Case 2 24 4 1.78 1.47 5.38 1.22 249.0
99 36 F White Non-Hispanic Case 13 29 5 2.50 3.27 4.38 2.49 1127.6
107 53 F White Non-Hispanic Contact 10 29 4 1.74 1.41 4.66 0.90 297.5
108 75 M White Non-Hispanic Case 16 41 7 1.37 0.88 3.47 1.36 557.5
110 27 M White Non-Hispanic Case 1 25 1 1.30 1.60 4.00 0.93 5.0
114 30 F White Non-Hispanic Case 15 36 7 1.65 1.92 3.53 1.55 110.9
115 65 F White Non-Hispanic Contact 20 41 6 2.10 3.28 4.32 3.27 1127.7
119 56 M White Non-Hispanic Case 13 48 3 1.36 1.26 4.41 1.59 650.3
120 56 F White Non-Hispanic Case 26 48 6 0.99 0.97 3.65 1.21 100.6
121 19 M White Non-Hispanic Contact 3 42 2 0.85 0.87 3.56 1.26 5.0
122 21 F White Non-Hispanic Contact 3 38 1 1.44 0.94 3.39 1.22 5.0
123 26 M White Non-Hispanic Contact 12 34 6 0.94 0.95 3.39 1.40 5.0
124 63 F Asian Non-Hispanic Contact 4 37 3 1.58 2.06 3.49 1.32 5.0
125 51 F White Non-Hispanic Case 10 26 3 1.92 3.49 3.86 1.24 126.5
127 24 F White Non-Hispanic Case 10 43 6 1.80 2.50 4.37 2.41 883.5
130 39 M White Non-Hispanic Contact 7 28 5 1.24 1.72 3.91 1.34 5.0
131 39 M White Non-Hispanic Case 5 25 4 1.46 1.38 4.44 1.03 7.8
132 36 M White Non-Hispanic Contact 10 50 6 2.15 1.76 4.84 1.97 5.0
134 27 F White Non-Hispanic Contact 16 22 5 2.51 2.18 6.84 1.94 2700.6
135 62 F White Non-Hispanic Case 8 31 6 2.20 2.02 3.80 1.13 350.0
140 63 F White Non-Hispanic Case 28 47 1 1.05 1.24 3.58 1.28 52.4
149 41 M White Non-Hispanic Contact 17 28 6 1.68 2.02 3.67 1.09 494.9
150 50 F White Non-Hispanic Contact 12 45 7 1.15 0.43 3.18 1.82 5.0
154 68 M Asian Non-Hispanic Case 16 30 9 3.19 2.19 4.85 1.29 928.2
157 50 M White Non-Hispanic Case 10 32 8 2.40 2.86 3.90 2.06 741.7
166 28 F White Non-Hispanic Case 13 45 2 1.27 0.66 3.45 0.94 5.0
167 50 F White Non-Hispanic Contact 11 41 6 1.43 3.71 3.93 8.74 5.0
172 38 F White Non-Hispanic Case 8 22 9 1.71 2.58 4.29 1.20 301.1
173 47 M White Non-Hispanic Case 5 47 7 2.57 4.14 4.78 4.48 646.9
178 26 F White Non-Hispanic Case 6 24 4 1.54 1.59 3.66 1.02 5.0
179 39 M White Non-Hispanic Contact 10 37 3 1.89 2.25 3.83 1.73 370.1
182 44 F White Non-Hispanic Contact 10 38 6 3.80 1.77 5.36 8.05 1503.7
183 43 F White Non-Hispanic Case 13 44 8 1.56 1.02 3.88 1.55 240.1
185 54 M White Non-Hispanic Case 11 44 8 3.51 1.39 5.55 2.11 1806.8
186 38 F N/A N/A Case 8 26 2 1.73 2.47 4.37 1.23 296.9
190 54 F White Non-Hispanic Case 18* 63 9 3.24 1.24 7.38 1.42 598.1
195 24 M White Non-Hispanic Case 18 42 5 2.74 2.55 5.01 2.33 1315.1
200 60 F White Non-Hispanic Case 17 39 7 2.40 1.00 4.38 1.51 1014.4
201 50 M White Non-Hispanic Contact 15 33 6 4.37 2.57 6.15 1.57 3897.4
202 57 M White Non-Hispanic Case 21 34 7 2.10 2.08 5.07 1.17 257.9
205 64 M White Non-Hispanic Case 7 36 4 4.51 0.70 6.12 1.69 924.4
222 28 M Asian Non-Hispanic Case 11 29 7 1.28 0.69 3.94 3.46 5.0
229 45 M White Non-Hispanic Case 10 63 4 2.92 1.42 4.90 1.58 1272.9
230 50 M White Non-Hispanic Case 18 33 7 3.80 0.47 3.48 0.88 5.0
232 38 F White Non-Hispanic Case 13 43 7 1.57 0.70 4.24 5.70 94.3
233 55 M White Non-Hispanic Case 20 41 3 2.07 2.11 4.51 1.07 173.2
241 36 M White Non-Hispanic Case 12 30 7 2.27 2.66 4.54 1.46 923.1
242 59 M White Non-Hispanic Case 10 42 6 4.91 1.94 4.81 2.16 1353.0
243 30 F Asian Non-Hispanic Case 6 26 5 2.92 2.57 5.06 1.14 1300.2
246 44 F White Non-Hispanic Case 10 38 7 2.05 2.79 6.09 1.32 566.0
255 33 M White Non-Hispanic Case 14 44 6 2.14 0.70 4.20 1.24 172.5
256 63 F White Non-Hispanic Case 27 42 6 1.72 1.96 4.26 7.79 141.6
258 52 M White Non-Hispanic Contact 14 48 6 2.64 1.20 4.52 1.85 4145.9
279 41 M White Non-Hispanic Case 7 38 8 1.68 2.13 3.77 1.90 308.9
280 59 M White Non-Hispanic Case 6 32 7 2.53 3.07 4.61 1.19 1072.1
302 47 F White Non-Hispanic Case 35* 49 7 1.48 0.97 4.06 1.26 5.0
310 34 F White Non-Hispanic Case 17 35 5 3.95 1.24 9.44 3.07 485.5
314 46 M White Non-Hispanic Case 11 38 7 2.12 0.88 4.56 1.51 667.1
315 29 F White Non-Hispanic Case 15 42 8 3.02 0.69 3.98 1.03 376.5
319 50 M White Non-Hispanic Case 5 38 6 3.71 2.28 3.79 1.05 5.0
323 39 F White Non-Hispanic Case 7 45 7 1.05 1.03 3.53 1.42 5.0
325 52 M White Non-Hispanic Case 16 38 8 2.25 1.47 4.83 2.28 1603.3
343 21 F White Non-Hispanic Case 16 49 5 1.63 0.94 3.37 1.70 5.0
352 44 M White Non-Hispanic Case 16 43 4 3.54 0.92 4.50 1.07 519.2
353 60 M White Non-Hispanic Case 14 49 6 5.38 1.12 5.69 1.05 855.5
356 22 F White Non-Hispanic Contact 16 38 3 1.37 0.61 2.98 1.09 5.0
357 27 F White Non-Hispanic Contact 34 56 5 7.49 1.10 2.77 1.13 5.0
364 29 M White Non-Hispanic Contact 14 49 6 0.97 0.58 2.90 0.89 5.0
366 41 F White Non-Hispanic Contact 9 34 7 0.98 0.52 3.51 1.19 5.0
373 35 F White Non-Hispanic Case 12 51 7 1.69 1.26 5.14 1.69 5.0
388 47 F White Non-Hispanic Contact 14 41 9 1.57 1.06 3.61 1.69 5.0
393 69 M White Non-Hispanic Case 23* 54 9 1.28 1.74 3.81 2.65 715.4
394 48 F Multiple Hispanic Case 7 67 4 2.05 0.87 4.34 2.02 1281.5
397 52 M White Non-Hispanic Case 22 45 8 3.32 0.59 5.01 0.87 1516.9
403 52 M Asian Non-Hispanic Case 18* 39 10 5.36 1.09 10.01 1.36 3887.8
406 65 M White Non-Hispanic Case 20 56 8 4.69 0.90 7.51 1.15 1288.7
410 34 M White Non-Hispanic Case 12 46 8 1.06 0.56 3.95 0.76 5.0
421 62 F White Non-Hispanic Contact 12 43 9 0.95 1.07 3.34 1.35 5.0
426 65 M White Non-Hispanic Case 18 51 6 2.07 0.55 3.95 1.49 804.8
437 43 F Asian Non-Hispanic Case 14 34 7 2.54 0.47 4.30 1.44 698.8
460 36 M White Non-Hispanic Case 11 39 6 2.94 3.18 5.51 2.80 1906.7
461 49 M White Non-Hispanic Case 7 39 5 3.38 0.94 4.67 2.02 1076.6
462 28 F White Non-Hispanic Case 16 45 5 1.36 0.38 3.07 1.11 5.0
470 28 F White Non-Hispanic Case 17 51 4 1.26 0.86 3.97 1.50 5.0
478 31 M White Non-Hispanic Case 16 52 4 1.43 0.93 3.70 1.97 263.2
481 28 F Asian Non-Hispanic Case 15 43 8 1.70 0.39 3.46 1.24 5.0
486 64 F White Non-Hispanic Case 11 41 10 1.70 1.00 3.68 1.29 5.0
500 46 M White Non-Hispanic Case 12 53 5 1.10 0.82 3.49 1.34 5.0
501 32 M Asian Non-Hispanic Case 18* 53 10 2.62 0.65 4.51 1.21 718.8
502 52 M White Non-Hispanic Case 16* 53 9 5.10 0.61 5.10 1.62 2171.8
506 46 M White Non-Hispanic Case 12 59 9 0.84 0.81 3.13 1.21 5.0
507 39 M White Non-Hispanic Case 15 60 8 1.92 0.96 4.56 1.52 5.0
509 36 M White Non-Hispanic Case 11 50 5 1.99 1.01 3.99 1.45 5.0
526 49 M Asian Non-Hispanic Case 11 34 7 3.36 1.45 5.88 1.57 4193.3
537 52 M White Non-Hispanic Case 15 45 6 1.47 0.95 3.65 1.58 923.3
539 73 F White Non-Hispanic Case 19* 54 10 2.82 0.63 4.46 1.45 487.9
547 59 M White Non-Hispanic Case 15* 36 9 2.97 1.53 5.08 2.59 2900.6
587 54 M PI N/A Case 17* 51 8 3.22 0.60 4.01 1.49 473.1
632 38 M White Non-Hispanic Contact 10 43 6 2.49 0.86 4.50 1.63 572.3
633 39 M White Non-Hispanic Contact 8 57 4 1.25 1.04 3.38 1.73 5.0
652 76 M White Non-Hispanic Case 18* 56 10 4.75 1.46 8.96 3.80 2324.0
664 45 F White Non-Hispanic Case 17* 42 10 1.68 0.43 3.93 1.32 5.0
675 47 M White Non-Hispanic Contact 31 47 5 0.79 0.93 2.94 1.38 5.0
*hospitalized, Sx=symptoms
Case/ContactEthnicity
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Shortness of breath 66 44.3
Headache 63 42.3
Loss of smell/taste 50 33.3




CAD, DM, COPD, 
asthma, cancer) 16 10.7
HTN (hypertension), CAD (coronary artery disease), DM (diabetes mellitus), COPD (chronic obstructive pulmonary disease)
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Extended data table 5. Sequences of cloned recombinant antibodies
C002 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTATCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGAGGGGAGACCATCTGATATTGTAGTGGTGGTGGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKN LYLQMNSLRAEDT VYYCAKE RPSDIVVVVAFDYWGQ TLVTVSSCATC TGACCCA TCTCCATCCTCCCTGTCTGCA C T GAGACA GTCACCATCACTTGCCG A T GA CATTAGCA CTATTT AATTGGTATCAGCAGAAACCA G AAGCCC TA GCTCCTG TCT GCTGCATCCAGTTTGCAAAGTGG T C CA GGT AGTG CAGTGGA TGG CAGATT CAC CACC C G T CA C A TTTT CAAC TAC ACTGTCAAC G TTACAGTACCCCTC GACGTTCGGCCAA G A AAG TGGAAATCAAADIQLTQSPSSLS SVGDRV IT RASQ ISSYL W QQKP KAPKLLIYA SLQSGVPSRFSGSGSGTDF LTISSLQPE FATYYCQQSYSTPR F QGTKVEIK
C003 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGGGGACACGGCCGTGTATTACTGTGCGAGGGATTACGGTGACTTCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGS YYADSVKGRFTISRDNSKNTLYLQMNSLRAGDTAVYYCARDY DFYFDYWGQ TLVTVSSAAT GTG TGACGCA TCTCCAGGCACCCTGTCTTT C C GG AAA AGCCACCCTCTCCTGC GG CA TCAGA TGTTAGCAGCACCTACTTAGCCT TACC CA AAAC T GCCAGGCTC CAG CTCCTCATCTA GGTGCAT CAGCA GGCCA T GCATCCCAGACAG TTCAGTGG AGT GGTCTGGGAC GAC TC C CTCACCATCAGC A T AG CT AAGAT T GCAGTGTATTACT TCAGCA TATGGTAGCT ACCT GGACTTTT G CA GGA AA CTGGA ATCAAAEIVLTQSP LSLSP ERA LS RASQSVSSTYLAWYQQ PGQAP LLIYGASSR GIPDRFSGS SGTDFTL ISRLEPE FAVYYCQQYG PRTF Q TKLEIK
C004 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTATCAGTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGCCCAGCATCACGTGGATATAGTGGCTACGATCATGGGTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAQVQLVQSGAEVKKP ASVKVSCK S YTFTGYYMHWVRQAP Q LEWMGWINPISGGTNYAQKFQ RV MTRDTSIST YMELSRLRSDDTAVYY ASPASRGYSGYDHGYYYYMDVWGK TTVTVSSGCCATC GATGACCCAGTCT ATCC CCCT G AT TGTAGGAGACAGAG CA CA CA TTGCCAGGCGAGTCA CATTAG ACTATTTAAATT GTA CAGCA AAACCA GAAAGC CCTAAGC CTGATCTA GATGCA CCAATTTGGAAACAGG T CCATCA GGTTCAGTGGAA TGGATCTGGGACAG TTTTACTTTCACC T A CAGCCTGCAGCCTGAAGAT TTGCAACATAT CTGTCAACA TATGATAATCTCCCTATC CCTTCGGCC A GGACAC ACTGGAGATTA ACAIRM QSPSSLSASVGDRVTIT QASQDISNYLNWYQQKP KAPKLLIYD SNLETGVPSRFSG GSG DF FTISSLQPEDIATYYCQQYDNLPITFGQ TRLEIK
C005 CAGGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGACCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTTACTAGCTCTGCTGTGCAGTGGGTGCGACAGGCTCGTGGACAACGCCTTGAGTGGATAGGATGGATCGTCGTTGGCAGTGGTAACACAAACTACGCACAGAAGTTCCAGGAAAGAGTCACCATTACCAGGGACATGTCCACAAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCCGAGGACACGGCCGTGTATTACTGTGCGGCTCCCCATTGTAGCGGTGGTAGCTGCCTTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLVQSGPEVKKPGTSVKVSCK S FTFTSSAVQWVRQARGQRLEWI WIVVGS NTNYAQKFQERVTI RDMSTSTAYMELSSLRSEDTAVYYCAAPHCSGGSCLDAFDIW Q TMVTVSSGAA TTGTGTTGACGCA TCTCCAGGCACCCT TCTTT CTCCA GGGAAAGAG CA CCTCTCCTGCA GGCCAGTCA A TTAGAA CAGCTACTTAGC TGG ACCAGCAGAAACCT CCAGGC CCCAG CTCCTCAT T TGGTGCATCCAGCAGGG CACTGGCATCCCAGAC GGTTCA TGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGAC GGAGCCTG A ATTTTGCAGTGTATTACT T AG AGTA GTAGCTCACCGTGGA G CGGC AAG GACCAAGGT GA TCA ACEIVLTQSP LSLSP ERA LS RASQS R SYL WY QKPGQAPRLLIYGA SRA GIPDRF SGSGTDFTLTISRLEPEDF VYY QQYGSSPWTFGQGTKVEIK
C006 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATCTTCAGTGACTACTGCATGAGCTGGATCCGCCGGGCTCCAGGGAAGGGGCTGGAATGGCTTTCATATATTAGTAATAGTGGTACCACCAGATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGGCAGGAACTCACTGTATCTGCAAATGGACAGCCTGAGCGCCGAAGACACGGCCGTTTATTACTGTGCGAGAAGGGGGGACGGTAGCAGCTCGATCTACTACTACAACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAQVQLVESGGGLVKP SLRLSCAASGFIFSDYCMSWIRRAPGKGLEWLSYISNSG TRYY DSVKGRFTISRDNGRNSLYLQMDSLSAEDT VYYCARR DGSSSIYYYNYMDVWGK TTVTVSSC T GT CTG CT A CCACCCT A CGTCTGGGA CCCCG ACA A G CACCGTCTCT TTCTGGAAGCAGCTCCA CATCGGAA AATACTG ACT G ACC GCAGC CCC GGAACGGCCCCCAAACT CT TC TAGTAATAAT AGCG CCCTCAGGGG C TGA CGATTCTCTGGCTCCAA TCTGGCACCTCAGCCTCCC C T AGTG GCT C GTCTGAGGATGAGGC G T A TTCTGTGCA CAT GGATG CAGC GAATGGT CGG TTCGGCGGAGGGACCAA CTGACC TCCTAGQSVL QPPSAS TPGQRV VSCSGS SNI SNTVNWYQQLP APKLLIYS NQRPS VPDRFSGSKSGTSASLAIS LQ EDE DYF A WDDSLN PVFGGGTKL VL
C008 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGACAGTTATTTCATATGATGGAAGGAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGAATTCGGTGACCCCGAGTGGTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGK LEWV VISYDGRNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREF DPEWYFDYWGQGTLVTVSSCATC ATG C A TCTCCTTCCACCCTGTCTGCATCT T GAGACA GTCACCA CACTTGCCG CAATCAGA TATTA TAGCTGGTTG C TG TATCAGCAGAAACCA GGAAAGCCCCTAA C CCTGATCTATAAGG GTCTAGTTTAGAAAGTGG T C CA GGT AG G CAGTGGATCTGG ACAGAAT CAC CACCATCAGCAGCCTGCAGCCTGAT ATTTTGCAACTTATTACTGCCAACAGTAT ATA T ATTGGACGTTC CCAAG GACCAAGGT GA ATC ACDIQMTQSPS LSASVGDRVTIT RANQ ISSWLAW QQKP KAPKLLIYK SLESGVPSRFS SGSGTEF LTISSLQPDDFA YY QQYNSYWTFGQ TKVEIK
C009 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCATGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTCCCCATTTAGTGCTTTAGGGGCCTCCAATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVQSGAEVKKP ASVKVSCMAS YTFTGYYMHWVRQAP Q LEWMGWINPNSGGTNYAQKFQ RVTMTRD SISTAYMELSRLRSDD AVYYCARDSPFSALGASNDYWGQ TLVTVSSA TCTGCCCTG C A CCT CTCCGCGTCC GGTCTCCTGGACAG CAG CAC A CTC T CACTGG ACC GCAGT AC TTGGT TTATAACT TGTCTCCTG TACCAACA CACCC GGC AAGCCCCCAAACTCATGATTTATGA GT TAAGCGGCCCT GTC TGAT GCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTC CTGA C TCTCTGGG CCA G TGA GATGAGGC GAGTATTACTGCAGCTCAGATGC GCAGC ACAATGTGGT T CGGCGGAGGGACCAA CTGA GTCCT GQS L QPPSAS SPGQSV ISC TSSDVGGYNYVSWY QHP KAPKLMIYEV KRPS VPDRFSGSKS NTASLTVSGLQAEDEAE Y SSD GSNNVVFGG TKLTVL
C010 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGCCAAGGGGCTGGAGTGGGTGGCAGTTATATTATATGATGGAAGCGGTAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGTTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGGATCGTGGATACAGCTCTGGTTACGTGGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPAKGLEWVAVILYDGSGKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGIVDTALVTWFDYWGQGTLVTVSSCATC TGACCCA TCTCCATCCTCCCTGTCTGCA C T GAGACA GTCACCA CACTT CCG GC A T GA CAT GCACCTATTT AATTGGTATCAGCAGAAACCA G AAGCCCCTA GCTCCTGAT TA GCTGCA C AGTTTGCAAAGTGG TCCCATCAAGGTTCAGTGGCAGTGGA TGG CAGATTTCAC CACC C G T CA C A ATTTT CAAC TAC ACTGTCAAC TTACA TACCCCTCCGT GA GTTCGG CAA GGAC A GGT AGATCAAACDIQLTQSPSSLS SVGDRV IT RASQSISTYLNW QQKP APKLLIYA SSLQSGVPSRFSGS SGTDF LTISSLQPEDFATYY QQSYSTPPW F QGTKVEIK
C013 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGGGAATCGACTACTTTATTGTAGTAGTACCAGCTGCTATCTAGATGCGGTTAGGCAGGGGTACTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAQVQLVQSGAEVKKP SSVKVSCK S GTFSSYAISWVRQAP QGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYY RGNRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKGTTVTVSSGAA TTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTG CTCCA GGGAAA A CCACCCTCTCCT CAG GCCAGTCAGA TGTTAGCA CT CTTA CCTGGTAC AAC AAACCT CCA GCTCCCAGGCTCC CA CT TGATGCATCCAACAGGGCCA TG CATCCCAG CA G CAGTG C GTGGGT TG GA G CTTCACTCTCACCATCA CA CCTAGAGCCTGAAGATTTT CAGTTTAT ACTGTCAGC C TAGCAACTGGCCCCTCACTTTCG CGGA GGA C AGGT GAGATCAAACEIVLTQ P LSLSP ERA LS RASQSVSSYLAWY QKP Q PRLLIYDASNRAT IP RF S SGTDF LTISS EPEDFAVY CQQRSNWPLTF TKVEI
C016 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGTGACCGCCCCTTATTGTAGTGGTGGTAGCTGCTACGGAGGTAACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGK LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVTAPY SGGSCYGGNFDYWGQGTLVTVSSCCATC ATG C A TCTCCATCCTCCCTGTCTGCATCTGTA GAGACAGAGTCACCA CACTTGCCA GAGTCAGGACATTA ACTATTT AATTG ATCAGCAGAAACCA G AAGCCC TA GCTCCTG TCT CGATGCATCCA TTTGGAAACAGGGGT C CAAGGT AGCGGAAGTGGATCTGGGACAGATT TAC T CACC C CAGC A T TT CAACATAT ACTGTCAAC GTA TAATCT CTCCTACT TCG CGGAGG ACCAA GT GAGATCAAACAIRMTQSPSSLSASVGDRVTIT QASQDISNYLNW QQKP APKLLIY NLETGVPSRFSGS SGTDF FTINSLQ EDIATYY QQYDNLPP F GTKVEIK
C017 GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTGGTACCATAGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTTTATTACTGTGCAAAAGCGGGCGTAAGGGGTATAGCAGCAGCTGGTCCCGACCTCAACTTCGACCACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGK LEWVSGISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAFYY AKA VRGIAAAGPDLNFDHW QGTLVTVSSAAT GT T ACACA TCTCCAGCCACCCTGTCTTTG C C GGGAAA GCCACCC CTCCTGCA GGCCAGT GTT CAGCTACTTA CCT ACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCAT T GATGC C AACAGGGCCACT CATCCCAGCCAGGTTCAGTG CAGTG GTCT GGACAGACT CACTCTC CCATCAGCAGCCTA AGCCT AAGATTTTGCAG T ATTAC TC GCAGC TATCACCTTC GCCAAG G CAC ACTGGAGATTAAACEIVLTQSP LSLSP ERA LS RASQSVSSYLAWYQQKPGQ PRLLIYDASNRATGIP RFSGSGSGTDF L ISSLEPEDF VYYCQQRITF Q TR EIK
C018 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGCTATACACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATTTTGACGATAGTTCGTTCTGGGCGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSNYAIHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKN LYLQMNSLRAED VYYCARDFDDSSFWAFDYWGQGTLVTVSSCATC TGACCCA TCTCCATCCTCCCTGTCTGC TCT T GAGACA GTCACCATCACTTGCCG GCAAGTCAGAGCATTCG CTATTTAAATTG TATCAACAGAAACCA GAAAGCCC TA GCTCCTGAT T GCTGCATCCAGTTTGCAAAGTGG T CT CA GGT AGTG CAGTGGA TGG CAGATTTCAC CACC C G T CA C TGATTTT CAAC TAC ACTGTCAAC TTACA TACCCCTCCGGC ACTTTT GCC GGGGACCAAG T AG T AAACDIQLTQSPSSLS SVGDRV IT RASQ IRSYL WYQQKP KAPKLLIYA SLQSGVPSRFSGSGSGTDF LTISSLQPDD ATYYCQQSYS PPA F Q KLEIK
C019 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGTTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCTAGAGTGCCCCGTGAGGGGACCCCAGGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVQSGAEVKKP ASVKVSCK S YTFTSYYMHWVRQAP Q LEWMGIINPSGGSTSYAQKFQGRVTMTRDTS STVYMELSSLRSEDTAVYY ARVPREGTPGFDPWGQG LVTVSSTCCTATGAGCTG CA A CCA CTCAGTGTCAG GG CCCAGG A GACGGCCAGGA AC TGTGGGGA AACAACATT AA A A T TG AC GGT CCAGCA AAGCCA CC GGCCCCTGTGCT GTCATC TT TGATAGCGACCGGCCCTCAGGGATC CTGAG GATTCTCTGGCTCCAACTC GGGAACA GGCCACC TGACCATCAACAG GTC AAGC G G ATG G C GACTAT ACTGTCAGGT T G ATAGTA TAGT AT ATGTGGTA GCGGAGGGACCA CTG G CC AGS EL QPPSVSVAPGKT RI CGENN SKSVHWYQQKP AP LVIYY SDRPSGIP RF SNSGNT TLTINRVE GDEADYYCQVWDSSSDHVVF KLTVL
C021 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGTTTGGCAATACTATGATAGTAGTGGTTCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLQESGPGLVKPSQTLSLT VSG SISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYY ARVWQYYDSS SFDYWGQGTLVTVSSG TAT G A CT AG T CACT TCCCTG C GT AC C GAGAGCC CT CATCTCCTGCAG TC G CAGA CCTCCTGCATA TAATGGATACAACTATTT GA T GTACCTGCA AAG CAGGGC GTC CCACAGCTCCTGAT TATTTG GTT AATCG G CTCCGGGGTCC T ACAGGTTCAGTGGC GTGGA CAGG ACAG TT TACACTGAAAATCAGCA A TGG G CTGAG ATG TGG GTTT TTACTGCATGCA GCTCT C AACTCCA ACTTTCGGCCCTGGGACCAAAGTGGA ATCA ADIVM QSPLSLPVTPGEPASISCRSSQSLLHSNG NYLDWYLQKP QSPQLLIYLGSNRAS VPDRFSGSGSG DFTLKI RVEAEDV VYYCMQ LQTPFTFGPG KVDIK
C022 CAGGTGCAGTTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCGTCACTTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGGTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTGGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGACATGCGGCAGCATACTATGATAGAAGTGGTTATTATTTCATCGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGQVQLQESGP LVKPSETLSVTCTVSG SISSSRYYW WIRQPPGKGLEWIGSIYYS STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHAAAYYDRSGYYFIEYFQHWGQGTLVTVSSG CAT CA ATG C AGTCTCCTTCCACC T TCTGCATC GTAGGAGACAGC TCA CATCA TTGCCGG CCAGTCA GTAT A TAG TGGTT CC GG ATC CA AAACCAG AA CCCC AGCTCC GA CTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATC AGGTTCAGCGG AGT GAT TGGG CAG ATTCACTCTCACC TCAGC CTGCA C T AT ATTTTGCAACTTAT ACTGC AACAGTATAAT ATTACCG TAC TTTGGCC G G ACCAAGC GGAGATCAAACDIQMTQSPS LS SVGDSVTI RASQSISSWLAW QQKP KAPKLLIYK SSLE GVPSRFS S SGTEF LTISSLQPDDFA CQQYNNYRYTF Q TKLEIK
C027 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGCAAGTGGAATTTATTGTAGTGGTGGAGACTGCTACTCATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGK LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAS IYCSGGDCYSYYFDYWGQGTLVTVSSCATC ATG C A TCTCCTTCCACCCTGTCTGCATCT T GAGACA GTCACCA CACTTGCCG CA TCAG TATTA TAGCTGGTTG C T TATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGG GTCTAGTTTAGAAAGTGGGGT C CAAGGT AGCGGCAGTGGATCTG G GAATTCACTCTCACCATC GCAG CTGC CTGATGATTTT AACT CCAAC GTATAATAGTT CGACGTTC CCA GGAC AAGGTGGAA TCAAACDIQMTQSPS LSASVGDRVTIT RASQSISSWLAW QQKP KAPKLLIYK SLESGVPSRFSGSGSGTEF LTISSLQPDDFA YY QQ NS STFGQ KVEIK
C029 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGCCGTGTATTACTGTGCGAGAACAATGTATTACTATGATAGTAGTGGTTCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLQESGPGLVKPSQTLSLT VSG SISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYY ARTMYYYDSSGSFDYWGQGTLVTVSSG TAT G A CT AG T CACT TCCCTG C GT AC C GAGAGCC CT CATCTCCTGCAG TC G CAGA CCTCCTGCATA TAATGGATACAACTATTT GA T GTACCTGCA AAG CAGGGC GTC CCACAGCTCCTGAT TATTTG GTT AATCG G CTCCGGGGTCC T ACAGGTTCAGTGGC GTGGA CAGG ACAG TT TACACTGAAAATCAGCA A TGG G CTGAG ATG TGG GTTT TTACTGCATGCA GCTCT CAAACTCCTCACAC TTCGG G A GACCAAGGTGGA A AACDIVM QSPLSLPVTPGEPASISCRSSQSLLHSNG NYLDWYLQKP QSPQLLIYLGSNRAS VPDRFSGSGSG DFTLKISRVEAEDV VYYCMQ LQTPHTFG TKVEIK
C030 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGCAAGTGGAATATATTGTAGTGGTGGTAACTGCTACTCATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGK LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAS IYCSGGNCYSYYFDYWGQGTLVTVSSCATC ATG C A TCTCCTTCCACCCTGTCTGCATCT T GAGACA GTCACCA CACTTGCCG CA TCAG TATTA TAGCTGGTTG C T TATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTCATCTATAAGG GTCTAGTTTAGAAAGTGGGGT C CAAGGT AGCGGCAGTGGATCTG G GAATTCACTCTCACCATC GCAG CTGC CTGATGATTTT AACT CCAAC GTATAATAGTT TCGACGTTC CCAAGGGACCAAGGTGGAA TCAAACDIQMTQSPS LSASVGDRVTIT RASQSISSWLAW QQKP KAPKLLIYK SLESGVPSRFSGSGSGTEF LTISSLQPDDFA YY QQ NS STFGQ KVEIK
C031 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACGACATGCACTGGGTCCGCCAAGCTACAGGAAAAGGTCTGGAGTGGGTCTCAGCTATTGGTACTGCTGGTGACACATACTATCCAGGCTCCGTGAAGGGCCGATTCACCATCTCCAGAGAAAATGCCAAGAACTCCTTGTATCTTCAAATGAACAGCCTGAGAGCCGGGGACACGGCTGTGTATTACTGTGCAAGAGTAGGGTATGATAGTAGTGGTTATTCGGGCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVQP SLRLSCAASGFTFSSYDMHWVRQATGK LEWVSAIGTAGD YYP SVKGRFTISRENAKNSLYLQMNSLRAGDTAVYY RV YDSSGYSGWYFDLWGRGTLVTVSSCATC ATG C A TCTCCATCCTCCCTGTCT CATCTGTA GAGACAGAGTCACCATCACTTGCCG G A TCAGA CATTAGCAGCTATTT AATTGGTATCA CA AAACCAGGGAAAGCCCCTAAGGTCCTGATCTATGCTGCATCCA T TGCAA GT GGTCCCAT A GG T T GC G GATCTGGGA AGAT TCAC TC CCATCA CAGTCTGCAACCT AGATTTTGCAACT ACTAC TC ACAG TTACA TACCCCTCCGCTCA TTTCG CGGAGGGACCAAG T AGATCAAACDIQMTQSPSSLSASVGDRVTIT RA QSISSYLNWYQQKP KAPKVLIY SSLQS VPSRFS SGSGTDF LTISSLQPEDFATYYCQQSYSTPP F KVEIK
C101 CAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCATCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATTCTACACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACTCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGTGCGGGACTACGGTGACTTCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGLIQP SLRLSCA SGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYTDSVKGRFTISRDNSKNTLYLQMNSLR ED VYYCVRDYGDFYFDYWGQ TLVTVSSAAT GTG TGACGCA TCTCCAGGCACCCTGTCTTT C C GG AAA AGCCA CCTCTCCTGC GGG CAGTCAGA TGTTAG CAG TACTTAGCCT TACC CA AAAC T GCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG CCACTGGCAT CAGA AG TTCAGTGG GGT GGTCTGAGACAGACTTC CTCT C A C CAGACTGGAGCCTGAAGA TGTGCAGTGTATTACT TCAG A ATGG AGCTCACCCCGGAC TTCGGCCAAGGGACCAAGGTGGAAATCAAACEIVLTQSP LSLSP ERA S RASQSVSS YLAWYQQKPGQAPRLLIYGASSR TGIPDRFSGGGSETDFTL ISRLEPED AVYYCQQYGSSPRTF Q TKVEIK
C102 CAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCATCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATTCTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGGGACTACGGTGACTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGLIQP SLRLSCA SGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSSAAT GTG TGACGCA TCTCCAGGCACCCTGTCTTT C C GG AAA AGCCA CCTCTCCTGC GGG CAGTCAGA TGTTAG CAG TACTTAGCCT TACC CA AAAC T GCCAGGCTCCCAGGCTCCTCATCTATGGTGCAT CAGCAGG CCACT GCATCCCAGA AG TTCAGTGG AGT GGTCT GGAC GACTTCACTCTCACCATCAGCAGACTG AG CT AAGA TTTGC G C ATTACT TCAGCA TATGG GCT ACCTCGGAC TTCGGCCAA GGACCAAGGTGGAAATCAAACEIVLTQSP LSLSP ERA S RASQSVSS YLAWYQQKPGQAPRLLIYGASSR TGIPD FSGSGSGTDFTL ISRLEPEDFAVYYCQQYG SPRTF Q TKVEIK
C103 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGGTCACTCAGTGGTTTCTACTGGACCTGGATCCGCCAGCCCCCAGGAAAGGGGCTGGAGTGGATTGGGGAAACCAATCATTTTGGAAGCACCGGCTACAAGCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACATGTCCAGGAACCAGTTCTCCCTGAAGGTGACCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAAAGCCCCTCCTCTACAGTGACTTCTCTCCTGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLQQWGA LLKPSETLSLTCAVS GSLSGFYWTWIRQPPGKGLEWIGETNHFGSTGYKPSLKSRVTISVDMSRNQFSLKVTSV AADTAVYYC RKPLLYSDFSPGAFDIWGQGTMVTVSSG AAT GT TT ACGCAGTCTCCAGGCACC T TCTTTG CTC A GGGAAA A CCACCCTCTCCTGCAGGGCCAGTCAGACTGTTA GC AA TACTT GCCT TACC CA AACCT GCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAAGAGGGCCACT GCATC G CAG TC GTG CAGT GT TG GACAGACTTCACTCTCAGCA CA CAGA T GA C TGAAGATTTTGCAGTGTATTACT TC AGTATACTACTACACCTCGGA TTC C GAGG CCAAGGT AG TCAAEIVLTQSP LSLSP ERA LS RASQTVTANYLAWYQQKPGQAPRLLIYG SKR GIPDRFSGS S TDFTLSISRLEPEDFAVYYCQ YTTTPRTF TKVEIK
C104 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCTCCTGCGCTGTCTATGGTGGGTCCCTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAGATCAATCATTTTGGAAGCACCGGCTACAACCCGTCCCTCAAGAGTCGAGTCACCATCTCCGTGGACACGTCCAAGAGCCAGTTCTCCGTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTCTATTACTGCGCGAGAAAGCCCCTCCTCTACAGTAACTTATCCCCTGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLQQWGA LLKPSETLSLSCAVY GSLSGYYWSWIRQPPGK LEWIGEINHFGSTGYNPSLKSRVTISVDTSKSQFSVKLSSV A D VYYC RKPLLYSNLSPGAFDIWGQGTMVTVSSG AATTGT TT ACGCAGTCTCCAGGCACCGTGTCTTTG CTC A GGGAAAGAGCCACCCTCTCCTGCTGGG CA TCAGA TGTTA GC AG TACT AGCCT TACC CA AACCT GCCAGGCTCCCAGGCTCCTCATCTATGGTG ATCCAGCAGGGCCACT GCATC GACAG TC GTG CAGTG GT TG GA AGAC TC CTCTCA CA CA TAGACTGGA CCTGAA A T TGCAGTA ATTACTGTC GCAGTACGG ACTACACCT GGA TTT G CGGAGGGACCAAG T AGATCAAACEIVLTQSP VSLSP ER LS WASQSVSASYLAWYQQKPGQAPRLLIYGAS RATGIPDRFS SGS TDFTLTISRLEPEDF VYY QQYGT PRTF TKVEIK
C105 CAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGTACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGGCGAGGGGTGGGAGCTACCATACGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGLIQP SLRLSCA SGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGS YY DSVKGRFTISRDNSKNTLYLQMNSLR EDTAVYYCARGE WELPYDYW QG LVTVSSC T GCCCTGACT A CCTCCCT CGTC GGGTCTCCTGGACA TCAGTCACCATCTCCTGCACTGGA CCAGCA T ACGTTGGTG TTATAA TATGTCTCCTG TACCAACAGCACCCAGGC A CCCCAAACTCATGATTTATG GTCAGTAAGC C TCAGGGGTCCCTGATCGCTTCTC GGCTCC AGTCTG C ACACGGCCTCC T A C TTTCTGGGCTCCAGGCTGA GATGAGGCTGATTATT CTGC CTCATAT AGGCAGCAACAAT TTGT TATTC CGGAGGGACCAAGCTGACCGTCCTAGQS LTQPPSAS SPGQSV ISC GTSSDV YKYVSWYQQHP KAPKLMIYEVSKRPS VPDRFSGSKS NTASLTVSGLQAEDEADYY SSYEGSNNFVVF TKLTVL
C106 CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGCCTCCGTCAGCAGTGGTAGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAATGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTGGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGAGAGCGGCCCGGTGGAACGTATAGCAACACCTGGTACACCCCAACCGATACCAACTGGTTCGACACCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQLQLQES PGLVKPSETLSLT VSGASVSSGSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSV AADTAVYY ARERPGGTYSNTWYTPTDTNWFDTWGQ TLVTVSSTCCTATGA CT ACACAGCCACCCTCA T TCAGTGGCCCCAGGAAAGAC CCAGGATTA CTGT G G ACAACATT AAG AA AGT TGCACTGGTACCA C AAG CA GCCAGGCCCC G GCTGG CATC ATTTT ATAGCGACCGGC T AGGGATCCCT AGCGA TCT TGGCTCCAACT TG GAAC CGGCCACC GA CATCAGCAG G GAA C G GGAT AGGC A TA TAC GT A GTGTG GATAGTAGT GT ATC TGTGG TTCGGCGGA G CAAG TGA CG C T GSYELTQPPSVSV PGKT RI CGGNNI SK VHWYQQKP QAPVLVIYFDSDRP GIPERFS SNS NT TLTIS VE DE DY CQVWDSSRDHVVF TKLTVL
C107 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAACTTTGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGGAAGCAGTGGCTGGTACAACCGGTTTTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVQSGAEVKKPGASVRVSCKASGYTFTSY FSWVRQAP Q LEWMGWISAYNGNTNFAQKLQ RV MTTDTS STAYMELRSLRSDD AVYYCAR EAVAGTTGFFDYWGQGTLVTVSSCAGTCTGTGCTGAC A CCA CTCAGCGTCT GGACCCCC GCAGA GTCACCATC TTGTTCTG AAG CCAACATCGGAAGTAAT ATGTA CT G ACCAGCAGCTCCCAGGAAC GCCCCCA CTCCTCAT T TAGGAAT ATC GCGG CTCAGG GTC CTG CCGATT TCTGG TC A GTCTGGCACCTCAGCCTCCCTG CCATCAGTGG C C GTCCG G ATGAG CTGATTAT ACTGT CA CATG G TGACAGCC GAGTGGTT G GGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGQSVL QPPSASGTPGQRVTISCS SSSNIGS YVYWYQQLPGTAPKLLIYRNNQRPS VPDRFS SKSGTSASLAISGLRSEDEADYY AAWDDSLS FVVFGGGTKLTVL
C108 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTACTAACTGGTGGAGTTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCTATCATACTGGGAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGTGAGAGATGGAGGACGACCCGGGGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLQESGPGLVKPSGTLSLT AVSG SISSTNWWSWVRQPPGK LEWIGEIYHTGSTNYNPSLKSRVTISVDKSKNQFSLKLSSV ADT VYYCVRDG RPGDAFDIWGQGTMVTVSSTCTGCCCTG CTCAG CT CCTCCGTGTCT GGTCTCCT GACAGTC ATCACCATCTCCT CACTGGAACCA CA T AC TTGGT TT AA TATGTCTCCT TACCAACAACACCCA C AGCC CC AACTC TGATTT TGATGTCAGTAATCGGCCCTCAGG GTTTCTAATCGCTTC CTGGCTCCAAGTCTGG ACACGGCCTCCCTGACCA C GG TCCAGGCTGAGGACGA GCTGATTATTACT CAACTCAT TACAAG AGCAGCACTCGAG CT CGGAACT GG CCAAGGTCACCGTCCTAGQSALTQPASV SPGQSITISC G SSDVGGYNYVSWYQQHP KAPKLMIYDVSNRP G SNRFSGSKS NTASL IS LQAEDEADYY NSYT SSTRVF TGTKV VL
C109 GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCGGAGACAACGCCAAGAACTCACTGTATCTGCACATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCTATACAGCTATGGTTAAGGGGGGGCTATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGK LEWVANIKQD SEKYYVDSVKGRFTISGDNAKNSLYLHMNSLRAEDTAVYYCAIQLWLR GYDYWGQGTLVTVSSC T GCCCTG CT A CCTCCCT GCGTC GGGTCTCCTGGACAGTCA CACCATC CC GCACTGGAACCAGCA TGACGTT GT T ATAACTATGTCTCCTGGTACCAACAGCACCCAGGC AAGCCCCCA C C TG T TA GA GTC AA C GCCCT A GGGTCCCTGATCGCTTCT TGGCT C AGT GG AAC CG CCTCCCTGACCGTCTCTG GCTCCAGGCTGA GATGAGGCTGAT ATTACTGCAGCTCATA GCA CA CAACAATTATGTGGTATT G C G GGGACCAAG T A CGTCCTAGQS LTQPPSAS SPGQSV ISC GTSSDVGGYNYVSWYQQHP KAPKLMIYEV KRPSGVPD FSGSKS NT SLTVSGLQAEDEADYYCSSY GSNNYVVF GTKLTVL
C110 CAGGTACAGCTGCAGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACATGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGATCGTTCCGGGACGACCCCCGTATAGCAGTGGCTGGCCCGGCTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLQQSGAEVKKPGESLKISCKGSGYSFTSYWI WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTIS DKSISTAYMQWSSLKASDTAMYYCARSFRDDPRIAV PADAFDIW QGTMVTVSSG C TCCAG TG C A TCTCC TC ACCCTG G ATC GTA GAGACAGAGTCA C TCACTTGCCG CCA T A A ATTAGTTAC GTTG CCTGGTAT A C AAACCA AAGCCCCTAA C CCTGA CTATCAG CGT TAGTTTAGAAAGTGGG T C TCA GGT AGC G AGTG TGGG CAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGAT ATTTTGCAA T A TACTGCCAACAGT AA AGTTACCCGTACA TTTTGGCCAG G A CAAG T AGATCAAACDIQM QSPS LSASVGDRVTIT R SQSISYWL W QQKP KAPKLLIYQ SLESGVP RFS SESG EF LTI SLQPDDF YY QQYNSYPYTF QG KLEIK
C111 CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGAGTAGAAGACTGGGGATATTGTAGTAGTACCAACTGCTATTCTGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQLQLQES PGLVKPSETLSLT VSG SISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVEDWGYCSSTNCYS AFDIWGQGTMVTVSSTCTGTGCTGACGCAG CACCCT GTGT TGAA CCC CAG CAGAGGG CACCATCTCCTGTTCTGG AGCAGCTCCA ATC GAAATAATGCT AAATT GTACC CA G CCCAGG AAGGCTCCCAAACTCCTCATCTA TATGATGATCTG GCCCTCAG G T TGACCGAT CTCTGGC TCTGGCACCTCAGCCTCCCTGGCCATCA TGG CTCCAGTCTGA AT A GCTGATTA TACT T C C TGGGAT ACAGCCTGAATGGCG TTGG TGTTCGGC GAGGGACCA GCTGACCGTCCTAQSVLTQPP VSE RQRV ISCSGSSSNIGN AVNWYQQVP KAPKLLIYYDDL P GVSDRFSGSKSGTSASLAISGLQSEDE DYYCAAWDDSLNGAWVFG TKL VL
C112 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCCATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGAGGATTACTATGATAGTAGTGGTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSSHAMHWVRQAPGK LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREDYYDSSGSFDYWGQGTLVTVSSC T TGCCCTG CTCA CCT CCTCCGTGTCTGGGTCTCCTGGACAGTC ATCA CATC CTGCA GGAACCAGCAGTGACGTT TG TTATAACTA GTCTCCTG TACCAACAACACCCAGGCAA GCCCCCA CTC G T TATGATGTCAGTAATCG CCCTCAG GGTTT T ATCG TTCTCTGGC TCTGGCAACACGGCCTCCCTGACCATCTCTG GCTCCA CTGA AC AGGC GA TATTACT CAGCTCATATACAAGCAGCAGCAC TGGGTGTTCGGC AGGGACC G TGACCGT TAGQSALTQP SVSGSPGQSITISC SSDVGGYNYVSWYQQHP K PKLMIYDVSNRPS V N FSGSKS NT SLTIS LQAEDEADYY SSYTSSSTWVF GTKLTVL
C113 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAACTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGGAGTAAACCCCGACGATATTTTGACTGGCGTAGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGK LEWVAVIWYD SNKYYADSVK RFTISRDNSKNTLYLQMNSLRAEDTAVYY AR VNPDDILTGVDAFDIW QGTMVTVSSCATC ATG C A TCTCCTTCCACCCTGTCTGCATCT T GAGACA GTCACCATCACTTGCCG C GTCAGA TATGAGTA CTGGTTG CCTG TAT A C AAACCA GGAACGCCCC A C CCTGA CTAT GGCGTCTAGTTTAGAAA TG TCCCA AGG TCAGC GC GTGGAT TG G GAA TC CTCT CCATC GCAG CTGCA CCTGATGATTTT AACT CCAACAGCATAAT GTTCCCCGCTC C CGGC A GGACCAAGG GAGATCAAACDIQMTQSPS LSASVGDRVTIT RASQSMSSWLAWYQQKPGN PKLLIYKA SLES VPSRFS SGSGTEFTL ISSLQPDDFA YYCQQHNSSPLTF KVEIK
C114 CAGGTGCAGCTGGTGGAGTCTGGAGGAGGGTTGATCCAGCCTGGGGGGTCCCTGAAACTCTCCTGTGTAGTCTCTGGGTTCACCGTCAGTAAGAACTACATCAGTTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAATGGGTCTCAGTTATTTTTGCCGGTGGTAGTACATTCTACGCAGACTCCGTTAAGGGCCGATTCGCCATCTCCAGAGACAACTCCAACAACACGCTGTTTCTTCAAATGAACAGCCTGAGAGTCGAGGACACGGCCATTTATTACTGTGCGAGAGGGGACGGGGAGTTATTCTTTGACCAATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGLIQP SLKLSCVVSGFTVSKNYISWVRQAPGKGLEWVSVIFAGGSTFYADSVKGRFAISRDNSNNTLFLQMNSLRVEDTAIYY RGD ELFFDQWGQ TLVTVSSC TC GTGCTG CT A CC CCCT AGTGTCTGGG CCC G G AGA TCACCATCTCCTGCACTGGG C CCAA ATC G AGGTTATG T T CACT GTACCAG AACT CC GGAAGA CCCCC AAGTCCTCATCT T GAAA AACATTC G CC CA AGG CCTGACCGATT TGG TC G TCTGGCAC TC GCCT CCTGGCCATCA T TCTC A CCTGAGGATGAGGCTCAAT TTACTGTCA TCT ATGA AGC GTCTCTAT CGGT TTCGG GGA GG AAGCTGACCGTCCTAQS L QPP VS APGQRV ISCTGTSSNI A YDVHWYQQLP RAPKVLIS NNIRPSEVPDRFS SRSGTSASLAI SL PEDEAQYY Q YDSSLYAVF GGTKL VL
C115 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGATAAAGCCAGGGCGGTCCCTGAGACTCTCTTGTACAGCCTCTGGATTCACCTTTGGTGATTATGCTATGACCTGGTTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGTAAAGCTTATGGTGGGACAACAGGATACGCCGCGTCTGTGAAATACAGATTTACCATCTCAAGAGATGATTCCAAAAGCATCGCCTATCTGCAAATGGACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTACTAGGTGGGACGGGTGGAGTCAACATGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGLIKP RSLRLSCTASGFTF DY MTWFRQAPGKGLEWVGFIRSKAYGGTT YAASVKYRF ISRDDSKSIAYLQMDSLKTED AVYYCTRWDGWSQHDYWGQGTLVTVSSTATTG GATG CTCAGTCT CACT TCCCTGTC GTCACCCCTGG GA CCGGCCT CATCTCCTGCA G C AGT A AGCCTC TGCATAGTAAT AAACAA ATTTCGATTGGTACCTGCAGA GCC GGGCAG CTCCAC GCT CT ATCTATTT G TCTAATCGGG CTCCGGGGTC CTG C G TCAGTGGCAGTGGATCAGGCACAGATTT AC T AAGATC G A TGG GGCTGAG ATG TGG GTT TTACTGCAT CAA TTC AC A TCCGTACACTTTTGGCCAGGGGACCAAGCTG AGATCAAACDIVM QSPLSLSVTPGEPASISCRSSQSLLHSN NNYFDWYLQKP QSPQLLIYL SNRASGVPDRFSGSGSGTDFTLKI RVEAEDV VYYCMQVLQIPYTF QG KLEIK
C116 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTACAGTACCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATTTCTACCATAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTYSTYAMHWVRQAPGK LEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFYHNWFDPW QGTLVTVSSA TTTTA C ACT AGCCCCAC T T TCGG G TCCG GG AGA T ACCAT C T CACCGGCAGCA TGGCA CATT CAA TA GTGCA T TACC CA CGCC GGGCAGTGCCCCCACCACTGTGATCTATGAGGAT AC AAA ACCCTCTGG G C CTG GGTTCTCTGGC C ATC CAGGT CTCCAACT TGCCTCCCTCACCATCTCTG ACTGA GACTGAG ACG GGC ACTACTAC GTC GTC T TGATAG G AATCATT GTG TATTCGGCGGAGGGACCAGG G CCGTCCTAGNFMLTQPHSVSESPGK V ISCT SS IASNYVQWYQQRP SAPTTVIYEDNQRPSGVPDRFS SIDRSSNSASLTISGLKTEDEADYY QSYD GNHWVVFG TRLTVL
C117 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCGAGGGGCTGGAGTGGGTGGCAGTTATTTCATATGATGGAAGCAATACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAAGACACGGCTGTGTATTACTGTGCGAGAGATCCCATATGGTTCGGGGAGTTATTATCTCCTCCTTTTGTTCACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGE LEWVAVISYDGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPIWFGELLSPPFVHFDYW Q TLVTVSSC T TGT CTGACTCAGCCGCCCTCAGTGTCTGCGG CCCAGG AGAA TCACCATC CCTGCTCTG AAGCAGCTCCAACATTGGGAATAATTT TATCCT TACC CA C CC GAACAGCCCCCAAACTCCTCATCTATGAAAATA T AG GACCCTCA GGATTC TGACCGATTCTCTGGCTCCAAGTCTGGCACG CAGC ACCCTG GCATCACC GACTCCAG CTGGG A GAG CCG TTATTA TGCG GCATGGGATAG A CCTGAGTGCTGGCGGGG ATG TTCGGA GGGACCAAGGTCACCGT CTAGQSVL QPPSVS APGQKVTISCSGSSSNIGNNLVSWYQQLP TAPKLLIYENNKRPSGIPDRFSGSKSGTSATLGITGLQT DEADYY GAWDSSLSA VYVFGT TKVTVL
C118 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTATTTATTACTGTGCGAGTGGATATACTGGCTACGATTATTTTGTGCGGGGGGACTACTACGGTCTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAQVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGK LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCASGYTGYDYFVR DYYGLDVWGQGTTVTVSSC C TGT CTG CTCA TCGCCCTCTGCCTCTGCCTCCC GGAG CTC CAAG TCACCTGCACTCTGAGCAGTGG CACAGCAGCTA G TC C CATCAGCA CAGCCAGAGA GGGCCC CGGTACTTG TG GCTTA A T TGG AGCC CA AAGGGGGA GGGATCCCTGATCGCTTCTCAGGCTCCAGCTCTG GGCTGAGCGCTA CTCACCA CTCC GC TC AG CTGAGGATGAG CTGACTAT TCAGACC GGGGCACTG CATTCTCG T CG CGGAGGGACCAA CTGACCGTCCTAGQPVLTQSPSAS SLG SVKLTCTLSSGHSSYAIAWHQQQPEK PRYLMKLN DGSHSKGDGIPDRFSGSSS AERYLTISSLQSEDEADYYCQTWGTGILVFGGGTKL VL
C119 CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTACGCACAGAAGTTACAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGCCAATCATGAAACAACTATGGACACTTACTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAQVQLVQSGAEVKKPGASVKVSCK S YTFTSYYMHWVRQAP Q LEWMGIINPS GSTSYAQKLQGRVTMTRDTS STVYMELSSLRSEDTAVYY ARANHETTMDTYYYYYYMDVWGKGTTVTVSSA TCTGCCCTGACT A CCTG CTCCGTGTCTGGGTCTCC G GTCGA CACCATCTCCTGCACTGGAACCAGCAGT AC GG TTATAA TATGTC CCTGGT CCAACGGCACCC GGCAAAGCCCCCAAACTCATGAT TA GATGTCAGTAATCGGCCCTCAGG GTTTCT ATCG TTCTCTGGCTCCAAGTCTGG ACACGGCCTCC C TCT T GGCTCC CTGAGGACGAGGC G T A TACTGCAGCTCATACACAAGCAGC GCACTT GTGGTG T GG GGAGGGACCCA CTGACC TCCTAQS L QPASVS SPGQSITISC SSDVGGYKYVSWYQRHP KAPKLMIYDVSNRPS V N FSGSKS NT SLTIS LQ EDEADYYCSSYTSSSTSVVFGG TQLTVL
C120 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCACTTATTTATCCCGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTCTATTACTGTGCGAGAGAGGGTATGGGTATGGCAGCAGCTGGTACGTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSLIYPGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGMGMAAAGTW QGTLVTVSSCCATCCGGATGACCCAG CTCC T CCCTG G ATCTGTAGGAGACACAGTCA CATCACTTGCCAGG GA T A ACATT A TATT AATTGGTATCAGCAGAAACCAGGG AAGCCCCTAAGCTCCTG T TACG TGCAT CA TTTGGAAACA GTCCCATCAAGGTTCAGTG AGTGGATCT GGACA A T TA TC CCATCAGCAGCCT CAG CT A G TATTG AA ATA TACTGT A C TATGATAATCTCCCTCAGA TTTC CGGAG AC A TGGAGA CAAACAIRMTQSPSSLSASVGDTVTITCQASQDISKYLNWYQQKP KAPKLLIYDASN E GVPSRFSGS SGTDFTFTISSLQPEDI TYYC QYDNLPQTF TKVEIK
C121 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCCCTGTCAGTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGCCCCACTGTTCCCCACAGGGGTGCTAGCTGGGGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAQVQLVQSGAEVKKP ASVKVSCK S YTFTGYYMHWVRQAP Q LEWMGWISPVSGGTNYAQKFQ RV MTRDTSISTAYMELSRLRSDDTAVYYCARAPLFPTGVLAGDYYYYGMDVWGQ TTV VSSA TCTGCCCTG CT A CCTG CTCCGTGTCTGGGT C TG A AGTC ATC CA C CTGCA GGA CC GCAGT TGTT GG TTATAACCTTGTCTCCTGGT CCAACA CACCCAGGCAAAGCCC CAAAC CATGATTT TG G GCAGT CGGCCCTCA GTTTCT ATCG TTCTCTGGCTCCAAGTCTGGCAACACGGCCTCC CAATCT GACTCCAGGCTGAGGACGAGGC G T ATTACTGCT T ATATGCAGGTAGTAGCACT TGGTATTC CGGAGGG CAAGCTGACC TC TAGQS L QPASVS SPGQSITISC SSDVGSYNLVSWY QHP K PKLMIYEG KRPS V NRF GSKS NTASLTIS LQAEDEADYY SYAGSSTLVF GGTKLTVL
C122 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGCTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTCTTTATAGCGGTGGTAGCTCATTCTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAAGACACGGCCGTGTATTACTGTGCGAGAGAAAGTGGGGATACAACTATGGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVLYSGGSSFY DSVKGRFTISRDNSKNTLYLQMNSLR EDTAVYYCARES D TMAFDYWGQGTLVTVSSCATCCAGTTG C A TCTCCATCCTTCCTGTCTGCATCT T GAGACA AG A C T CGGGCCA TCAG CA TA AGTTAT TAGCCTGGTATCAGCAAAAACCAGGG AAG CCC AGCTCCTG TCTATGCTGCATCCACTT G AAAGT GTCCCATCAAGGT AGCG CAGTGGATCT GGACAGAAT CACTCTCACA TCA CAGCCTGCAGCCT AAGATTTTGCAACT ATTACT TCAACA CTTAATA TGACTCGTACACTTTTGGCCAGGGGACCAAGCT GAT AAACDIQLTQSPSFLSASVGDRV IT RA QGI SYLAW QQKP KAPKLLIYA STLQSGVPSRFSGS SGTEFTLTISSLQPEDF TY CQ LNSDSYTFGQ TKLEIK
C123 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGGTCACCGTCAGTAGGAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGATCTATCTGCTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGEVQLVES GGLIQP SLRLSCAASGVTVSRNYMSWVRQAPGK LEWVSVIYSGGS YY DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSAAFDIWGQGTMVTVSSCATCCAGTTG C A TCTCCATCCTTCCTGTCTGCATCT T GAGACA A A C T CCGGGCCA TCAG CATTA A TTA TTAGCCTGGTATCAGCAAAAACCAGGG AAGCCCC AGCTCCTG TCTATGCTGCATCCACTT G AAAGT GTCCCATCAAGGT AGCG CAGTGGATCT GGACA AAT CACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGT A C C TA AGTTAC C CCAGCCT C C A G ACACGACTGG GAT AAACDIQLTQSPSFLSASVGDRV IT RA QGI SYLAW QQKP KAPKLLIYA STLQSGVPSRFSGS SGTEFTLTISSLQPE FATYYCQQLNSYPPAFGQ TRLEIK
C124 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCCGGAGTGGGTTTCATACATTAGTAGGAGTAGTAGTACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTATTACTGTGCGAGAGAAGGGGCTAGAGTGGGAGCTACATATGACACGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVQP SLRLSCAASGFTFSGYSMNWVRQAPGK PEWVSYISRSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDT VYYCARE ARVGATYDTYYFDYWGQGTLVTVSSAATTGT TT ACACAGTCTCCAG ACCCTGTCT TG C C GGGAAA GCCACCCTCTCCTGC GG CA T GA T TTAGCAGCTACTT CCTG TACCAACAGAAACCTGGCC GGCTCCCA GC CC CA CTATG G AT CA C GGGCCACTGGCAT CCAGCCAGGTTCAGTGGCAGTG GTCTGGGACAGACT CA CTC CCATCAGCAGCCTAGAG CT A G TTTTGCAGT TA TACTGT AGC CGTAACAACTG CCTCCCGAGTGG C TTCG CCAAGGGACCAAGGT AAATCAAACEIVLTQSPA LSLSP ERA LS RASQSFS YLAW QQKPGQAPRLLIYD S RAT IPARFSGSGSGTDF LTISSLEPEDFAVYY QQRNNWPPEW FGQGTKVEIK
C125 CAGGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGACCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTTACTAGCTCTGCTGTGCAGTGGGTGCGACAGGCTCGTGGACAACGCCTTGAGTGGATAGGATGGATCGTCGTTGGCAGTGGTAACACAAACTACGCACAGAAGTTCCAGGAAAGAGTCACCATTACCAGGGACATGTCCACAAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCCGAGGACACGGCCGTGTATTACTGTGCGGCACCTTATTGTAGTGGTGGTAGCTGCTCTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLVQSGPEVKKPGTSVKVSCK S FTFTSSAVQWVRQARGQRLEWI WIVVGS NTNYAQKFQERVTI RDMSTSTAYMELSSLRSEDTAVYYCAAPYCS GSCSDAFDIW Q TMVTVSSGAA TTGTGTTGACGCA TCTCCAGGCACCCT TCTTT CTCCA GGGAAAGAG CA CCTCTCCTGCA GGCCAGTCA A TTAGCAGCAGCTACTTAGC TGG ACCAGCAGAAACCTGGC AGGC CCCAG CTCCTCAT T TGGTGCAT CAGCAGGGCCACTGGCATCCCAGAC GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGAC GGAGCCTG A ATTTTGCAGTGTATTACT T G AGTA GTAGCTCACC TG ACG TCG CAAGGG C AA TGG ATCAAACEIVLTQSP LSLSP ERA LS RASQS S SYLAWY QKPGQAPRLLIYGA SRA GIPDRFS SGSGTDFTLTISRLEPEDFAVYY QQYGSSPWTFGQ TKVEIK
C126 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCTCCTGCGCTGTCTCTGGTGGCTCCATCGGTAGTTACTTCTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGATATCTCCATTACAGTGGGAGCACCAACTACAACCCCTCCCTGAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAATCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGATTGCAGTGGCTACGCGGAGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLQESGPGLVKPSETLSLS AVSG SI SYFWSWIRQPPGKGLEWIGYLHYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLQWLRGAFDIWGQ TMVTVSSAATTTTA C CTCAGC CC CT TGT TC GAG TCCG GGAAGA G TAAC AT TC T C CCGGCAGCA T GCA C TT C AACTAT T C T GTACC CA CGCCCGGG AGTGCC CCACCACTGTGATCAATGAAGATAAC AAA CCCTCT G GTC TGAT GGTTCT TG CT C TCGA A CTC TCCAACTCTGCCTCCCTCAC ATCTCTG ACTGAA A TGAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCAGC AT TG TATT GGCGGAGGGACCAAG T A CG C TAGNFMLTQPHSVSESPGK V ISCT SS SIASNYVQWYQQRP SAPT VINEDNQRP G PDRFSGSIDSSSNSASLTISGLKTEDEADYY Q YDSSNLVF GGTKLTVL
C127 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGACGGCGCACCCCCGGAGGATCCAAGGGGTATTTTTTTTGGGGCCGGGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAQVQLVQSGAEVKKP ASVKVSCK S YTFTGYYMHWVRQAP Q LEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDD AVYYCATAHPRRIQGVFFLGPGVWGQGTTVTVSSA TCTGTGCTG C A CCA CTCAGCGTCTGGGA CCCCGGGCAGA G CAC A CTCTT TTCTGGAAGC GCT CAACATCG A TAATACT TA CTGGTACCAGCAGCTCCCA A GGCCCCCA ACTCCTCATCT T G ATA TCAGC GCCCTCA GGGTCCCTGACCGATTCTCTGGCTCCAAG T GCACCTCAG C CCCTGGCCATCA TG GCTC A T TGAGGATGAGGC GA TA TACTGTGCA ATGGGATGACAGCCTGAATGGCGTGG A CGGCGGAGGGACCAAGCT AC GTCCTAGQSVL QPPSAS TPGQRV ISCSGSSSNIGSNTVNW Q LPGTAPKLLIYSNNQRPSGVPD FSGSKS TSASLAISGLQSEDE DYY AA DDSLNGV F GGTKLTVL
C128 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCACCTATGCCATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTACTGGTAGTGGTCGTGACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAACTGAACAGCCTGAGAGCCGAGGACGCGGCCGTGTATTCCTGTGCGAACCACCCTCTGGCATCAGGCGACGACTACTACCACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGK LEWVSTI GSGRDTYYADSVKGRFTISRDNSKNTLFLQLNSLRAEDA VYSCANHPLASGDDYYHYYMDVW K TTVTVSSAAAT GT TG CG A TCTCCAGGCACCCTGTCTTTG C C GGGAAA AG CA CC CT CTGC GGGCCAGTCA A GTTAA CAGG TT GCCT GTACCAGCA AAA CTGGCCAGGCTCCCA CTCCTCAT TATGGTGCGTCCAG A G CCACTGGCA C CAG GAGGTTC TGGCAGTGGATCTGGGA A ACTTCACTCTCACCATCAGCAGACTGGAGTCTGAA ATTTTGCAG GTA CACT TCAGCAATATG TAGCTCAA G CGCTCACTTT GGCGGAGGGACC A GTG A ATC ACEIVLTQSP LSLSP ERA LS RA QSVNS QLAWYQQKPGQAPRLLIYGASSRATGIPERFS SGSGTDF LTISRLESE FAVYH QQYGSSR LTF KVEIK
C130 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAACTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAGGCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGATCCCGACCGACTCCTGACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCCTCAGQVQLVQSGAEVKKP ASVKVSCK S YTFTNYYMHWVRQAP Q LEWMGIINPS GSTGYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYY ARSRPTPDWYFDLWGRG LVTVSSTCCTATGAGCTG CA A CCA CTCAGTGTCAG GG CCCA G A GACGGCCAGGA AC TGTGGGGG AACAACATT AAGT A A TGTG ACTGGT CCAGCA AAGCCA CC GGCCCCTGTGCT GTCATC TT TGATAGCGACCGGCCCTCAGGGATC CTGAG GATTCTCTGGCTCCAACTC GGGAACA GGCCACC TGACCATCAGCAG GTC AAGC G G ATG G C GACTAT ACTGTCAG T TGGGATAGTAGTAGTGATCA CCGGGGGTGGTATTCGGCGGAG AC AAGCTGAC GTC TAGS EL QPPSVSVAPGKT RI CG NN SKSVHWYQQKP AP LVIYY SDRPSGIP RF SNSGNT TLTIS VE DE DYYCQVWDSSSDHPGVVF GGTKL VL
C131 CAGGTGCAGCTGGTGCAGTCTGGGTCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATCCTTGCTTTAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGTCAATCAAGCAGTAACTACTCCCTTCTCCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAQVQLVQSGSEVKKPGSSVKVSCKAS GTFSSYAFSWVRQAP Q LEWMGRIIPILALANYAQKFQGRVTITADKSTS AYMELSSLRSEDTAVYYCARVNQAVTTPFSMDVWGQGT VTVSSGAAATAGTG TG CG A TC AGCCACCCT GTGT TCCAGGG AAAG CA CCTCT CTGCAGGGCCAGT A A TTAGCAGCAAC A C TG TA CA CAGAA CCT GCCAGGCTCCCAGG TCCT A CTATGGTGCATC CAGG C ACTGGTATCCCAGCCAGGTTCAGT CAGTGGGTCT G ACAGAGT CAC CTCA CATCAGCAGCCT CAG CT A G TTTTG AGT TA TACTGTCAGCA TATAATA CTGGCCGATCAC TTCGGC A G ACGACT AG TTAAACEIVMTQSPA LS SP ER TLS RASQSVSSNLAWY QKPGQ PRLLIYGAS R TGIPARF GS SG EF LTISSLQSED VYYCQQYNNWPITFGQGTRLEIK
C132 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTAATAACTGGTGGAGTTGTGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCTATCATAGTGGGAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGGGGGGATACAGCTATGGGCCCCGAATACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLQESGPGLVKPSGTLSLT AVSG SISSNNWWSCVRQPPGK LEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSV DT VYYCAR GDTAM PEYFDYW QGTLVTVSSTCTGCCCTG CTCAG CT CCTCCGTGTCT GGTCTCCT GACAGTC ATCACCATCTCCT CACTGG CA CA T AC TGGT GTTATAA TAT TCTCCT TACCA CAAC CCCA CAAAGCC CCAAACTC TG TTTATGATGTCAGTAATCGG CCTCAGG GT TCTAATCG TTCTCTGGCTC AAGTCTGGCAACACGG CTCCCTGACCA C GG T AG CTG G ACGAG CTGATTAT ACTGCAGCTCATATAC AGCAGCA CA T TTTTG T GGCGGAGGGACCAAGCT ACCGT CTAGQSALTQPASV SPGQSITISC G SSDVGGYNYVSWYQQHP KAPKLMIYDVSNRPSG SNRFSGSKS NTASL ISGLQAEDEADYY SSYTSSSTLLFGGGTKL VL
C133 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATTATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATTCGGACGTAGATACATCTATGGTTACTTGGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK LEWVAVILYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSDVDTSMVTWFDYWGQ TLVTVSSCATC ATG C A TCTCCATCCTCCCTGTCTGCATCT T GAGACA GTCACCA CACTTGCCG GC A TCAGA CATTAG CTATTT AA TGGTATCAGCAGAAACCA G AAGCCCCTA GCTCCTGAT T GCTGCATCCAGTTTGCAAAGTGG T C CA GGT AGTG CAGTGGA TGG CAGATTTCAC CACC C G T CA C A TTTT CAAC TAC ACTGTCAAC T A A TACCCCTCCGTGGAC TTCGGCCAAGGGACC AG T AAATCAA CDIQMTQSPSSLSASVGDRVTIT RASQSISSYL W QQKP KAPKLLIYA SLQSGVPSRFSGSGSGTDF LTISSLQPEDFATYYCQQSYSTPPWTF Q TKVEIK
C134 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAACTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGATGGTAGCACATACTACGCAGGCTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGATCCCCTTATAACTGGACCTACCTATCAATACTTTCACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGK LEWVSAISGSDGSTYYAGSVKGRFTISRDNSKN LYLQMNSLRAEDTAVYYCAKDPLITGPTYQYFHYWGQGTLVTVSSTCCTA G CTG CA A CCACCCT AGTGTCAGTG CCCAGG AAGACGGCCAGGA ACCTGTGGGGGAA CAA T AAGTAAAAGTG CT GTACCAGCA AGCCAGGCCAGGCCCCTGT CT GTCATC TTATGATAGCGA C C TCA GGATC TGAG GATTCTCTGGCTCCAACTCTGGGA CACGG CACC T ACC C G GG CGA G TGA A C CA GTGTGGGATAG GT G AT G C GGGGGTGGTTTT GGCGGA A A CTGA GTCCT GSYELTQPPSVSVAPGKT RI C GNNI SKSVHW QQKP QAPVLVIYYD DRPS IPERFS SNSGNT TLTISRVE DEAE HCQVWDSSSDRP VVF G TKLTVL
C135 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACCATTTGATGGAAGAAATAAGTACTACGCAGACTCCGTGACGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGTAGTAGTGGTTATCTTTTCCACTCTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK LEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYW QGTLVTVSSCATC ATG C A TCTCCTTCCACCCTGTCTGCATCT T GAGACA GTCACCA CACTTGCCG GCCAGT GA TATTAGTAACTG TG C TG TTTCAGCAGAAACCAGGGAAAGCC TAAGCTCCTGATCT GA GCGT TAGTTTAGAAAGTGG TCCCATCA GGTTCAG G CAGTGGA TGG CAGA T CAC CACC C GCA CCT CAGCCTGAT TTTTGCAACTTAT ACTGCCAACAGTATAATA T ATC GTGGACG TC G C AG AC A TGGAGA CAAACDIQMTQSPS LSASVGDRVTIT RASQSISNWLAWFQQKP KAPKLLIYE SLESGVPSRFSGSGSGTEF LTISSLQPDDFA YY Q YNSYPWTF Q TKVEIK
C138 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTACCTATTGGATGAGCTGGGTCCGCCAGCCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTATGTGGATTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGACGACACGGCCGTGTATTACTGTGCCGGGGGGACATGGCTACGATCCTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVQP SLRLSCAASGFTFSTYWMSWVRQPPGK LEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYY A TWLRSSFDYWGQGTLVTVSSA TTTTA C ACT AGCCCCAC T TCGG G TCCG GGAAGA T ACCAT CCTGCA CGGCAGC GTGGCA CATT CCA CAAC T TGCA TGGTACCAGCAGC C GGGCAGTGC CCCACC CTGTGATCTATGAGGA AACCAAA ACCCTCTGG G C CTG GGTTCTCTGGCTC ATC CAG T CTCCAACT TGCCTCCCTCA CATCTCTG TGA GACTGA GACGAGGCTGA TACTACTGT GTCT T AGCAGCAATTGGGTGTTC G G A GGA AA CTGA CGTCCTAN MLTQPHSVSESPGK V ISCT SS SIASNYVQWYQQRP SAP VIYEDNQRPSGVPDRFS SIDSSSNS SLTISGLKTE EADYY QSYD NWVF GGTKLTVL
C139 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTCTGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGGGGGGGCCTACAGCTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAEVQLVES GGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK LEWVAVISYDGSNKYSADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK AYSYYYYMDVWGKGTTVTVSSCATC ATG C A TCTCCATCCTCCCTGTCTGCATCT T GAGACA GTCACCA CACTTGCCA G GA TCAG ACATTAGCAACTA TTAAATTGGTATCAGCAGAAACCA G AAGCCCCTAAGCTCCTG TCT CG TGCA CAATTTGGAAACAGG T C CA GGT AGTG AGTGGA TGG CAGATTT ACT TCA C TCAGCAGCCTGCAGCCTGAAGATATT CAACATATTACTGTCAACAGTAT ATAATCTCCCGCTC TTCGGCGG G ACCAAGGT A TCAADIQMTQSPSSLSASVGDRVTIT QASQDISNYL WYQQKP KAPKLLIY NLETGVPSRFSGS S TDFTFTISSLQPEDIAT YCQQYDNLPL F TKVEIK
C140 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAGTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCACTTATTTATAGCGGTGGTAGCACATTCTACGCAGACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCGAGAACACGCTGTATCTTCAAATGAACACCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATCTGTATTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAEVQLVES GGLVQP SLRLSCAASGVTVSSNYMSWVRQAPGK LEWVSLIYSGGS FY DSVKGRFTISRDNSENTLYLQMNTLRAEDTAVYYCARDLYYYGMDVWGQ TTVTVSSCATC TG C A TCTCCATCCT CCTGTCTG A C T GAGACA A C T CGGGCCAGTCAGGGCATTA A TTA T AGCCTGGTATCAGCAAAAACCAGGG AAGCCCC AGCTCCTG TCTATGCTGCATCCACTT G AAAGT GTCCCATCAAGGT AGCG CAGTGGATCT GGACA AAT CACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACT ATTACT TCAACA CTTAA GTTACTCTTACACTTTTGGCCA GG CCAAG TGGAGATCAAACDIQLTQSPSFLSASVGDRV IT RASQGI SYLAW QQKP KAPKLLIYA STLQSGVPSRFSGS SGTEFTLTISS QPEDFATYYCQQLNSY YTFGQGTKLEIK
C141 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGTTCTGGGTCCGCCAGGCTCCGGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGGCGGATTTAGGATATTGTACTAATGGTGTATGCTATGTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAEVQLVES GGVVQPGRSLRLSCAASGFTFSSYAMFWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADLGYCTNGVCYVDYWGQGTLVTVSSA TTTTA C ACT AGCCCCAC T T TCGG G TCCG GG AGA T ACCAT CCT CACCGGCAGCA TGGC CATT CCA CAACTAT TGCA TGGTACCA CAGC CCC GGCAGTGCCCCCACCACTGTGATCTATGAGGAT AC AAA ACCCTCTGG G C CTG GGTTCTCTGGC C ATC CAG T CTCCAACTCTGCCTC CTCACC TCTCTGGACTGA GACTGAG ACG GGC ACTACTACT TCAGTCTTATGATAGC GCAA TGGGTG TC GCGGAGGGACCAAGCTGACCGTCCTAGN MLTQPHSVSESPGK V ISCT SS IASNYVQWYQQRP SAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYY QSYDSSNWVF GGTKLTVL
C143 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAGTGTCAGCACCAAGTACATGACATGGGTCCGTCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTCTTTACAGCGGTGGTAGTGATTACTACGCAGACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACGCTTTATATCTTCAAATGAACAGCTTGAGAGTCGAGGACACGGGTGTTTATTACTGTGCCAGAGACTCGTCGGAAGTCCGTGACCACCCCGGGCACCCAGGGCGCTCGGTGGGGGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGEVQLVES GGLVQP SLRLSCAASGFSVSTKYMTWVRQAPGKGLEWVSVLYSGGSDYY DSVKGRFTISRDNSKNALYLQMNSLRVEDTGVYYCARDSSEVRDHPGHPGRSVGAFDIWGQ TMV VSSC T GCCCTG CT A CCTGCCTCCGTGTCTGGGTCTCCTGGACAGTC ATCA CA C CTGCACTG A CA CA ATGTTGGGA TTA A CCTTGTCTCCTGGTACCAACAGTA CCAGGCA AGC CCCAAACTCTTAATT TT AG G A TAA CG TCCTCAGGG TTTCTAAT GCTTCTCTGGTTCCA GTCTGGCAACACGGCCTCCCTGACAATCTCT GGCTCCAGGGT AA ACGAGGCT ATTATTATTG GC AT T CAG CTAG ACTTTC TGTTCGGCGGAGGGACCAAGCT ACCGTCCTAGQS LTQPASVS SPGQSITISC NDVGSYTLVSWYQQYPGKAPKLLIFEGTKRSSGISNRFS SKSGNTASL I GLQGEDE DYY CSY ASTFVFGGGTKLTVL
C144 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAACAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAAATCCAAGAACACGCTGTATCTTCAAATGAACAGGCTGAGAGCCGAGGACACGGCCGTGTATTATTGTGCGAGAGAAGGGGAGGTAGAAGGGTATAACGATTTTTGGAGTGGTTATTCTAGAGACCGTTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGS YY DSVKGRFTISRDKSKNTLYLQMNRLR EDTAVYYCARE EVEGYNDFWS YSRDRYYFDYW Q TLVTVSSC T GCCCTGACT A CCT CCT TGTCTGGGT CCTGGA AGTC ATCA CATC CTGC TGGA CAGCAGTGAC TT GTG TTATAACTATGTCTCC GG ACCAACAACACCCAGGCAA CCCCAA CTCATG TTTAT AT T AGTAATCG CC TCAGGGGTTTCTAATCGCTTCTCTGGCTCCA GTCT GCAACACGGCCTCCCTG CCA CTCT GGCTCC GG T AGGACG GGCT ATTATTACTGCA CTCATA C CAGCAG AC CGAGTCTTC AAC GGGACC AG C CGTCCT GQS LTQPASVS SPGQSITISC G SDV YN VSWYQQHP KAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTIS LQAEDEADYY SS TSSSTRVF TGTKVTVL
C145 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCAGCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGTACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGAAGGGGAGGTAGAAGGGTATTACGATTTTTGGAGTGGTTATTCTAGAGACCGTTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFSVSSNYMSWVRQAPGKGLEWVSVIYSGGS YY DSVKGRFTISRDNSKNTLYLQMNSLR EDTAVYYCARE EVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSSC T GCCCTGACT A CCT CCT TGTCTGGGT CCTGGA AGTC ATCA CATC CTGCA TGGA CA CAGT AC TT GTG TTATAACTATGTCTCC GGTACCAACAA ACCCAGGCAAA CCCCCAA C CATG T TAT AT T AGTAATCG CC TCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCT GCAACACGGCCTCCCTGACCATCTCT GGCTCC GG T AG ACG GGCT ATTATTACTGCA CTCATA C CAGCAC AC CGA TCTTC AAC GGGACC GG CACCG CCT GQS LTQPASVS SPGQSITISC G SDV YN VSWYQQHP KAPKLMIYDVSNRPS VSNRFSGSKSGNTASLTIS LQAEDEADYY SSYTSSTTRVF TGTRVTVL
C146 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGACTCACCTTCACTGCCTATAGAATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGCTCTCATCAATTAGTAATACAAATGGCGACATATACTATGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAATTCTCTGTATCTGCAAATGAACAGCCTGAGGGCCGACGACACGGCTGTATATTACTGTGCGAGAGATGTTGCATCTAACTACGCTTACTTTGACCTTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVKP SLRLSCAASGLTFTAYRMNWVRQAPGKGLEWLSSISNTN DIYY DSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYYCARDVASNYAYFDLWGQGTLVTVSSC T TGCCCTG CT A CCT CCTCCGTGTCTGGGTCTCCTGGACAGTC ATCACCATCTCCTGCACTGG ACCA GTGACATT GTGTTTA AAC ATATCTCCTGGA CCAACAA ACCCAGGC AAGCC CC AA TC TGATTTATGATGTCACTAATCG CCCTCAG GGTTT T ATCG TTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTG CATCTCTGGGCT C G CTGA AC AGGC GA TATTATT CAGCTCATATAGAGGCAGCAGC CCCTATG CTTC GA CT GGA AA GTCA CGTC TAGQS L QPASVS SPGQSITISC DIGVYNY SWSQQHPGK PKVMIYDV NRPSGVSN FSGSKSGNT SLTISGLQAEDE DYYCSSYR PYVF T TKVTVL
C147 GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGATTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCACCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACTCAGTGACCGCTGGTACAGTCCGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVQSGAEVKKP ESLKISCK SGYRFTNYWI WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTIS DKSITTAYLQWSSLKASDTAMYYCARLSDRWYSPFDPWGQGTLVTVSSGCTGTG TGACCCA A CCCTCACTGACTGTGTCCCC AGGGACAGTCACTC C TGTGG CC G ACTG A CTGTCACCA T GTCATT TCCCTACTGGTTCCAGCAGAAGTCTGGCCAAGCCCCCAGGACACTG TTTATG AA AAG A CAA CACTCCTGGAC C GC C GTTCTC G TCC T TTG GGGCAAA T CCCT ACC TTTCG TGCGCAGCCTGAGGATGAGGCTGAT ATTACTG TGC CT TATAGTGGTGCTCGGC GTGTTC C GAG ACCAAGCTGACCGTCCTAGQ VVTQEPSLT SPGG V L C SSTGAVTSGHYPYWFQ KS QAPRTLIYETSIKHSWTP RFS SLL KAALTLS AQPEDE DYYC LSY G RPVFGG TKL VL
C148 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCAGAGACTCTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAATTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCGCATACTACGTAGACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACCCTGTATCTTCAAATGAACAGCCTGAGACCCGAGGACACGGCTGTGTATTACTGTGCGAGAATCGCAAACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAEVQLVES GGLVQP SQRLSCAASGFTVSSNYMSWIRQAPGKGLEWVSVIYSGGSAYYVDSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARIANYMDVWGKGTTVTVSSAATAGT AT ACGCA TCTCCAGCCACCCTGTCTGTG C C GG AAA AG CA CCTCTCCTGC GGGCCAGTCA AGTGTTA C A TTA CCT TACCAGCAGAAACCTGGCCAGGCTCCCA CTCCTCAT TATGGTGCATCCAC A G CCACTGGT C CAACCAGGTTC TGGCAGTGGGTCTGGGACAGAGTTCACTC C C T AGC C TGC TCTGAA AT T C G TTAT ACTGCCAG AGTATAATAACT CCTCC CTCACTTTC CGG G A CAA GTGGAGATCAAACEIVMTQSPA LSVSP ER TLS RASQSVSSHLAWYQQKPGQ PRLLIYGAS RAT IPTRFSGS SGTEFTLT SSLQSEDFAVYYCQQYNNWPPLTF TKVEIK
C150 GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGTAGCCTCTGGATTCACCTTCAGTAGCTACTGGATGCACTGGGTCCGCCAAGTCCCAGGGAAGGGGCCGGTGTGGGTCTCACATATTAACAGTGAAGGGAGTAGCACAAACTACGCGGACTCCGTGAGGGGCCGATTCACCATCTCCAGAGACAACGCCAAGGACACGCTATATCTTCAAATGAACAATCTGAGAGCCGAGGACACGGCTGTATATTACTGTGCAAGACCGACGGCTGTAGCAGCAGCTGGCAATTACTTCTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAEVQLVES GGLVQP SLRLSCVASGFTFSSYWMHWVRQVPGK PVWVSHINSE SS NYADSVR RF ISRDNAKDTLYLQMNNLRAEDTAVYYCARPTAVAAAGNYFYYYGMDVWGQ TTVTVSSC TCTGCCC G CT A CCT CCT GTGTCTGGGT CCTGGA AGTC ATCACCATCTCCTGCACTGG ACC GCAGT ACGTTG TT T ATAACTTT TCTCC GGTACCAACAA ACCCAGGC AGCCCCCAAACTCATG TTT TG G TCAGTAAT GCCCTCTGG G TCTAATCG TTCTCTGGCTCCAAGTCTGGCAA ACGGCC CCTGATCATC G CT AG CTG G A GAGGCTG TTAT A TGC G TCATATAGAAGCAGCAGCACTCTGGTGTTCGGCGGGGGGACC A CTGAC GTCCTAGQS LTQPASVS SPGQSITISC G S DVGYYNFVSWYQQHP K PKLMIYEVSNRPS VS RFS SKS NTASLIISGLQ EDE D SSYRSSSTLVF GGTKL VL
C151 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAACATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATGCATTAGTAGTAGTAGTAGTTACATATACTACGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAGAGGGGGTATGACGGTGGTAAAACCCCCCCATTTCTTGGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVKP SLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSCISSSSSYIYY DSVKGRFTISRDNAKNSLYLQMNSLRAEDT VYYCARER YDG KTPPFLGGQGTLVTVSSA TTTTA C CT AGCCCCAC T T TCGGAG TCCG GGAAGA G ACC T CCT CACCGGC GCA TGGCAGCATT CAA T T GCAGT TACC CA CGC CG GCAGTGCCCCCACCACTGTGATC TG G ATAACCAAAGACCCTCTGG GTCC TGATCGGTTCTCTGGCTC ATC CAG T CTCCAACTCTGCCTC CT ACC TCTCTG ACTGA GACTGAG ACG GGC ACTACTACTGTCA TCT ATGATAGCAGC TTATTGGGTG GGCGGA GG CCA G TGACCGTC TAGN MLTQPHSVSESPGK V ISCT S IA NYVQWYQQRP SAPTTVIYEDNQRPSGVPD FSGSIDSSSNSASLTISGLKTEDEADYY QSYDSSNYWVFGG TKLTVL
C153 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTTATAGCACATACTACGTAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGTGGGGGGAGCACATAGTGGCTACGACGGATCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGYS YYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGGAHSGYDGSFDYWGQGTLVTVSSC T GCCCTGACT A CCT CCT TGTCTGGGT CCTGGA A TC ATCA CATC CTGCA TGGA CA CAGT TGTT G TTA AACCT GTCTCCTGGTACCAACAGCACCCAGGCAA CCCC AACTCATG T TATG GGCAGTAAGC C TCAGGGGTT AATCGCTTCTCTGGCTCC AGTCTGGC A ACGGCCTCC T ACAATCTCTGG CTCCAGGCTGA GACGAGGCTGATTATT C CT CTCATATGCAG TA TAG ACTT GGTG C G GGA ACCAAGCTGACCGTCCTAGQS LTQPASVS SPGQSITISC G SDV SYNLVSWYQQHP KAPKLMIYE SKRPSGVSNRFSGSKSGNTASLTIS LQAEDEADYY SYAGSSTWVF KLTVL
C154 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATGTCATATGATGGAAGTAGTAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTGTCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAACAGGCGGGCCCATATTGTAGTGGTGGTAGCTGCTACTCCGCGCCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGK LEWVAVMSYD SSKYYADSVK RF ISRDNSKNTLCLQMNSLRAEDTAVYYCAKQAGPYCSGGSCYSAPFDYWGQ TLVTVSSCATC ATG C A TCTCCATCCTCCCTGTCTGCATCT T GAGACA GTCACCATCA TT CCA GA TCAG CATTAGCAACTA TTAAATT GTATCAGCAGAAACCA G AAGCCCCTAAGCTCCTG TCTACG TGCA CCAATTTGGAAACAGG TCCCATCA GGTTCAGTG AAGTGGA TGG CAGATTT ACT TCA C TCAGCAGC TGC CCTGA ATATTGCAACATATTACTGTCAACAGTATGATAATCT GATCACCT C GCCA GGA ACGACT GAGAT AAACDIQMTQSPSSLSASVGDRVTIT QASQGI NYLNWYQQKP KAPKLLIYD SNLE GVPSRFSGSGS DFTFTISSLQPEDIATYYCQQYDNLPITF TRLEIK
C155 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCATCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATTCTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTTGGAGAGTTCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLR ED VYYC RDF EFYFDYWGQ TLVTVSSAATAGTGATG CG A TCTCCAGCCACCCTG GT TCTCCAGG GAAA AG CA CCTCTCCTGCAGGGCCAGT A A GTTAG CAA TTA CCT TACCAGCAGAAACCTGGCCAGGCTCCCA CTCCTCAT TA GGTGCATCCAC A G CCACTG T C CAGCCAGGTTC TGGCAGTGGGTCTGGGACAGAGTTCACTC C C T AGC CCTGC TCTGAA ATTTTGC G TTATTACT TC CAG ATAAT AC GGCC C GACGT C C A C AAG TGG GATCAAAEIVMTQSPA LSVSP ER TLS RASQ VS NLAWYQQKPGQ PRLLIYGASTRATAIPARFSGS SG EFTLTISSLQSEDFAVYYCQQYNNWPRTF Q TKVEIK
C156 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAATAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATCCTTTCCCCTTAGCAGTGGCTGGGACGGGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGK LEWVAVISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY AKDPFPLAVAGT YFDYWGQ TLVTVSSTCCTATGAGCTGACTCA CCACCCTCGGTGTCAGTGGCCCCAGGA AGAC CCAGGATTTCCTGTGGGG AA CAACA TGGAAGTA A ATGTG ACTGGTACCA AGA CCAGGCCAGGCCCCTGTGCTGGTCGTC TG TGATAGCGACCGGC TCAGG ATCCCTGAGCGATT T TGGCTCCAAC TGG GCCACCCTGACCATCAGCAGGGTC AGCCG GATGA GCCGACTATTACTGT AGGT TGGGATAGTAG AGTG TCCTTG TGTTCGGCGGAGG CAAGCTGA GTCCT GSYEL QPPSVSVAPGQTARISC GNNI SKNVHWYQQKP QAPVLVVY D DRPSGIPERFS SNSGNT TLTISRVE DEADYYCQV DSSSDPWVFGGGTKLTVL
C164 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAGTGTCAGCACCAAGTACATGACATGGGTCCGTCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTCTTTACAGCGGTGGTAGTGATTACTACGCAGACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACGCTTTATATCTTCAAATGAACAGCTTGAGAGTCGAGGACACGGGTGTTTATTACTGTGCCAGAGACTCGTCGGAAGTCCGTGACCACCCCGGGCACCCAGGGCGCTCGGTGGGGGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGEVQLVES GGLVQP SLRLSCAASGFSVSTKYMTWVRQAPGKGLEWVSVLYSGGSDYY DSVKGRFTISRDNSKNALYLQMNSLRVEDTGVYYCARDSSEVRDHPGHPGRSVGAFDIWGQ TMV VSSC T GCCCTG CT A CCTGCCTCCGTGTCTGGGTCTCCTGGACAGTC ATCA CA C CTGCACTG A CA CA ATGTTGGGA TTA A CCTTGTCTCCTGGTACCAACAGTA CCAGGCA AGC CCCAAGCTCTTAATT TT AG TCA TAAGCG TCCTCAGGG TTTCTAAT GCTTCTCTGGTTCCA GTCTGGC ACACGGCCTCCCTGACAATCTCT GGCTCC GGGT AA ACGAGG ATTATTATTG GC AT T CAG CTAGCACTTTC TGTTCGGCGGA GGACCAAGCT ACCGTCCTAGQS LTQPASVS SPGQSITISC NDVGSYTLVSWYQQYPGKAPKLLIFEVTKRSSGISNRFS SKSGNTASL ISGLQGEDEADYY CSY ASTFVFGGGTKLTVL
C165 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCGTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGTAGCTATGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATCGTTGGTATAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACGGCGGACAAATCCTCGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATCTCCTGGACCCCCAGCTAGATGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGQVQLVQSGAEVKKP SSVKVSCK S GTFSSYAINWVRQAP QGLEWMGRIIPIVGIANYAQKFQGRVTITADKSSSTAYMELSSLRSEDTAVYY RDLLDPQLDD FDIWGQGTMVTVSSGAA TTGTGTTGACGCA TCTCCAGGCACCCT TCTTTG CTCCA GG AAAG GCCACCCTCTCCTGC G GCCAGTCA AGTGTTAG CA TACTTAGCCTGGTACCAGCAGAAACCT CCAGG T CCAGGCTCCTC T TATGGTGCATCCAGCAGGG CACTGGC TC CA CAGGTT A TGGC GTGGGTCTGGG CAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAG GTA TACT TCAGCAG ATG TAGCT A C TGGACGTTCGGCCAAGGGACCAA GTGGAAATCA CEIVLTQ P LSLSP ERA LS RASQSVSSTYLAWYQQKPGQAPRLLIYGASSR GIPD FSGS SGTDFTL ISRLEPE FAVYYC QYGSSPWTFGQ TKVEIK
C201 GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTGGTAGTATAGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGAC ACGGCCTTGTATTACTGTGTAAAAGGGGTCGAGTATAGCAGCTCGAGCAACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGK LEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYY VK VEYSSSSNFDYWGQGTLVTVSSC TC GG TGACCCAGTCT CATCTTCT TGTCTGCATCT TA G GACA A CACCATCACT TCGGGCGAGTCAGG TAT AGCAGCT G TAGCCTGGTATCAGCA AACCAGGGAAA CCCCTAA CTCCT ATC TGT GAATCCA TTTGCAAA T GG TCCCATCAAGGTTCAG GGC TGG TCTGGGACAGATTT AC CTCACT TCA CAGCCTGC CCTGA ATTTTGCAACCTACTA TGTCAAC GGCTAACAGTTTCCCTCTCACTTTCG GGAGG C AG T AA TCAAACIRMTQSPSSVS SVGDRV ITCR SQ SWLAWYQQKPG APKLLIYVESSLQ GVPSRF GSGSG DFTLTISSLQPEDF TYYCQQANSFPLTF TKVEIK
C202 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTAAGACTCTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCACTTATTTATAGCGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATACCCTTGGTAGGGGGGGCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVQP SLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYSGGS YY DSVKGRFTISRDNSKNTLYLQMNSLR EDTAVYYCARDTL RGGDYWGQ TLVTVSSCATC TG C A TCTCCATCCTCCCTGTCTGCATCTGT GAGACA AGTCACCATCACTT CCAGG GA TCAG ACATTAGCAACTA T AAATTGGTATCAGCAGAAACCAGGG AAGCCCC AGCTCCTG TCTACG TGCATCCAATT GGAAAC GTCCCATCAAGGT AGTG AGTGGATCT GGACA A T TA TCACCATCAGCAGCCT CAGCCT A G TATTGCAACATATTACTGT A C TATGATAATCTCCCTCGGAGTTTTGG CA GACCAAGCTGGA A AACDIQLTQSPSSLSASVGDRV IT QASQDI NYLNWYQQKP KAPKLLIYD S LETGVPSRFSGSGSGTDF FTISS QPEDIATYYCQQYDNLPRSF Q TKLEIK
C204 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGAACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTTAGCACCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGCTGGCACATTCTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGAGAGAGCGATTGTGGTAGTACCAGCTGCTATCAAGTCGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSAISGSGAGTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT VYYCARESDCGSTS YQVGWFDPW QGTLVTVSSACATC TTG C TCTCCATCCTCCCTGTCT CATCTGTA GAGACAGAGTCACCA CA TTGCCGGGCAAGT GAGCATTAG CTATTT AATT TATCAGCAGAAACCAGGGAAAGCCCC AAGCTCCTGATCTATG TGCA C AGTTTGCAAAGTGG TCCCATCAAGGTTCAGTGGCA TGGATCTGGGACAGATTTCACTCTCA CATCAGCAGTCTGCAACCTGA ATTTTGCAA T CTACTG CAA AGAGTTACAGTACCCCTCCGTGGA GTTC GCCAGG GACCAA GGA ATCAAACDIQLTQSPSSLSASVGDRVTIT RA Q IS YLNWYQQKP KAPKLLIYAA SLQS VPSRFSGS SGTDF LTISSLQPEDFATYYCQQSYSTPPWTF Q TKVEIK
C205 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGACACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATCATCAACCCTAGTGGTGGTAGCACAAGCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCTGTGTATTACTGTGCTAGGGGGCCGGAACGGGGTATAGTGGGAGCTACTGACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVQSGAEVKKP ASVKVSCK S HTFTSYYMHWVRQAP Q LEWMGIINPS GSTSYAQKFQGRVTMTRDTS STVYMELSSLRSEDTAVYYCAR PERGIVGATDYFDYWGQ TLVTVSSGAA TTGTGTTGACGCA TCTC AGGCACCCTGTC TTGTCTCCA GGGAAAGAGCCACCC CTCCTGC GGGCCAGT GAGTGTTA CAG TACTTAGCCT TACCAGCAGAAACCTGGCCAGG T CCAGGCTCCTCATCT T G G ATC C GGCCACT GCATCCCAGACAGGTTCA TGGCA GGGTCT GGACAGACTTCACTCTCACCATCAGCA ACTGGA CCTGA GATTT CAGTGTAT ACTG CA CA TATGTT GCTCACCGT GAC TT GGCCAAGGGACCA GGTGGAGAT A ACEIVLTQ P LSLSP ERA LS RASQSVSSSYL WY QKP QAPRLLIYGAS R TGIPDRFSGSGSGTDFTL ISRLEPEDF VY CQQYVSSPWTFGQGTKVEIK 
C207 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGAACCCATCGGCCAGCCACTGCTATGGTGGGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGK LEWVSAISGSG STYYADSVKGRFTISRDNSKN LYLQMNSLRAEDTAVYYCAKEPIGQPLLWWDYWGQGTLVTVSS AAAT GT TG CACA TCTCCAGCCACCCTGTCTTTG C C GGGAAA GCCACCC CT CTGC G GCCAGT GAGTGTTAG CTA TTA CCTG TAC AAC AAACCTGGCCAGGCTCCCAGGC CC CA CTATG G AT CA C GGG CACTG CAT CCAG CAGG TCAGT GC GTGGGTCTG GACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCA TT CA C GCGTAG ACT G CC GGGGGTTC CCAAGGG CAA TGGA ATCAAACEIVLTQSPA LSLSP ERA LS RA Q VSSYLAW QQKPGQ PRLLIYDAS R TGIPARFS SGSG DF LTISSLEPEDFAVYYCQQRSNWPRGF Q TKVEIK 
C208 GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGAAGTGGAGCAGCCTGAAGGCCTCGGACAGCGCCATGTATTACTGTGCGAGGGGGCCCAACCTCCAGAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVQSGAEVKKP ESLKISCK SGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTIS DKSIS AYLKWSSLK SDSAMYYCARGPNLQNWFDPWGQ TLVTVSS G A TTGTGTTGACGCAGTCTCCAGGCACCCTG TTGTC CCAGGGGAAAGAG CA CCTCTCCTGCAG CCA T A A TTAG G CAGCTACTT GCCTGG ACCAGCAGA ACCTGGCCAGG TCCCA G CTCAT T TGGTGCTTCCAGCAGGG C CTGGCATC CAG CAGGTT A TGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAG A ACT GAGCCTGA ATTTTGCAGTGTATTACTGTCA CA TATGGTAGCTCGCTCACTT CG CGGGG ACCAAGGT GAGATCAAAEIVL QSP LSLSP ERA S R SQSVSGSYL WYQQRP Q PRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLTFG TKVEIK 
C209 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGTCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCCTACATGGANCTGAGCAGCCTGANATCTGANGANACGGCCGTGTATTACTGTGCGANAGGGTTCAGCCTGACTTGGTACTTCGATCTCTGGGGCCGTGGNNCCCTGGTCACCGNCTCCTCAGQVQLVQSGAEVKKS ASVKVSCK S YTF SYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMXLSSLXSXX AVYYCAX FSLTWYFDLWGRGXLVTXSS TCCTATGAGCTG CA A CCA C C TGTCA TGG CCCAG A AGAC GCCAGGA AC TGTGGGGGA A ATTGGAAGCAAAA TGTGCACTGGTACCAGCAGAA CCAGGCCATGCCCCTGTACTGGTC TCTATGATGATAGCGACCGGCCC CAGG AT CCT AGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCAC C ACCA C GG CGA G C GGGATGA AC CA GTGT GAT TACTGG G TC TCC G GGT TT G C AGGGACCAAGCTGAC GT CTS ELTQPPSVS APGKTARI CGGNNI SKSVHWYQQKP HAPVLVVYDDSDRPSGIPERF SNSGNTATL ISRVE DE YY QVWDSTG HPDVVF GGTKLTVL 
C210 GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGTACATTCTACGCAGACTCCGTGAAGGGCCGATTCACCTTCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTGATGGCCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGEVQLVES GGLIQP SLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGS FYADSVKGRFTFSRDNSKNTLYLQMNSLR EDTAVYYCARDLMAYGMDVWGQ T VTVSS CATCCAGTTG C A TCTCCATCCTTCCTGTCTGCATCT T GA ACA AGTCACCA C T CGGGCCA TCAG CATTAGCA TTA TTAGCCTGGTATCAGCA AAACCAGGG AAGCCCC AGCTCCTG TCTATGCTGCAT CACT TGCAAAGTGGGGTCCCATCAAGG TCA C G G GGATCTGGG AGAA TCAC TC CAAT AGCCTGCAGCCT AGATTTTGCAACT ATTAC TC ACAGC A A TTACCCTCAG CAC TTC CGGAG AC AAG TGGAAATCAAACDIQLTQSPSFLSASVGDRV IT RA QGISSYLAWYQQKP KAPKLLIYA STLQSGVPSRFSGS SGTEFTLTISS QPEDFATYYC QLNSYPQ FG KVEIK 
C211 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGAATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATTCTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTGTATTACTGTGCGAGAGACTACGGTGACTTCTACTTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVQP SLRLSCAASEFTVSSNYMSWVRQAPGK LEWVSVIYSGGS FY DSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARDY DFYFDFWGQ TLVTVSS AATAGT ATGACGCA TCTCCAGCCACCCTGTCTGT TCTCCA GG AAAGAG CA CCTCTCCTGC GGGCCAGTCA AGTGTTAG CAA TTAGCCTGGTAC A CA AAACCTGGCCAGGGTCCCA CTCCTCATCTATGGTGCATCCAC A G CCACTGGTATC CAGCCAGGTTC TGGCAGTGGGTCTGGGA A AGTTCACTCTCAC TCAGCA C TGC TCTGAA AT T C G TTAT ACTGTCA CAGTATAAT AC GGCCCC GACGT C C A C AAG TGG GATCAAAIVMTQSPA LS SP ER LS RA QSVSSNLAWYQQKPGQ PRLLIYGASTRAT IPARFSGSGSG EF LTISSLQSEDFAVYYCQQYNNWPRTF Q TKVEIK 
C212 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCGTCACCGGCTATTATATACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCCCTAACAGTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCTGGGTCACCATGACCAGGGACATGTCCATCACCACAGCCTACATGGAGCTGAGTAGACTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGGGAACGATATTTTGACTTGGGTGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGQVQLVQSGAEVKKP ASVKVSCK S YTVTGYYIHWVRQAPGQGLEWMGWISPNSGGTNYAQKFQ WV MTRDMSITT YMELSRLRSDDTAVYYCARERYFDLGGMDVWGQGTTVTVSS CT AGCCTGC TCC T T G CTCCT GA AGT TCACCA CTCCTGCA TGG A CAGC G GA GTTGGGAGT ATA CTTGT T C GT CCAA AGC CCCAGGCAAAGCCC CAAACTC TGATTTA AGGAC GTA GCGGCCCTCAGGGGTTTCTAATCG TT TCTGG TCCAAGTCTGG A GG CT CTG CAATCTCTG GCTC A GCTGAGGACGAGGCT ATTATTAC G CT ATATGCAGGTAGTAGCACTCGGCTATTCGGCGGAGGGACCAAGCTGACCGTCCTALTQPASVSGSP QSITISC SSDV SYNLVSWYQQHPGKAPKLMIYEDSKRPSGVSNRFSGSKSGNTASLTIS LQAE EADYYC SYAGSS RLFGGGTKL VL 
C214 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATATGGTATGATGGAAGTAATAAACACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGTAGGGCGGGTGACGACCTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGK LEWVAAIWYD SNKHYADSVK RFTISRDNSKNTLYLQMNSLRAEDTAVYY ARDVGRVTTWFDPWGQGTLVTVSS CATC TGACCCA TCTCCATCCTCCCTGTCTGCA C T GAGACA GTCACCATCACTT CCG TCAGA CATTAGCAGCTA TTAAC TGGTATCAGCAGAAACCA G AAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAA T GGGTCCCATCAAGGTTCAGTGGCA TGGATCTGGGACAGATTTCACTCTCA CATCAGCAGTCTGCAACCTGA ATTTTGCAACT ACTACTG CAA AGAGTTACAGTAC CCTCCGT GA GTTCGGCCAAGGGACCAAGGT AGATCAAACDIQLTQSPSSLS SVGDRV IT RASQSISSYLTWYQQKP KAPKLLIYA SSLQSGVPSRFSGS SGTDFTLTISSLQPEDFA YYCQQSYSTPPW F Q KVEIK 
C215 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTACTGATAGTGGTGATGGCACATTCTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTTTATTACTGTGCGTCCGAAGAGGACTACAGTAACTACGTGGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGK LEWVSAI DSGDGTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT VYYCASEEDYSNYVGWFDPWGQGTLVTVSS ACATC TTG C TCTCCAT CCCTG G ATCTGTAGGAGACAGAGTCA CA CA TTGCCG GCAAGT GA CATTAG CTATTT AAT G TATCAGCAGAAACCAGGGAAAGCCC A GCTCCTGATCTATG TGCA C AGTTTGCAAAGTGG TCCCATCAAGGTTCAGTGGCAGTGGATCTGG ACAGATTTCACTCTCACCATCAGCA TCTACAACCTGA ATTTTGCAA T ACTACTG CAA AGAGTT C TACCC TCCGTGGAC TTC CCAAGGGACCAAGGT AA TCADIQLTQSPSSLSASVGDRVTIT RA QSIS YLNWYQQKP KAPKLLIYAA SLQS VPSRFSGSGSGTDF LTI SLQPEDFATYYCQQSYSTPPW F Q TKVEIK 
C216 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACGACATGCACTGGGTCCGCCAAGCTACAGGAAAAGGTCTGGAGTGGGTCTCAGCTATTGGTACTGCTGGTGACACATACTATCCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGAAAATGCCAAGAACTCCTTGTATCTTCAAATGAACAGCCTGAGAGCCGGGGACACGGCTGTGTATTACTGTGCAAGAGATCGGGGAAGCAGTGGCTGGTACGGCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCCTCAGEVQLVES GGLVQP SLRLSCAASGFTFSSYDMHWVRQATGK LEWVSAIGTAGD YYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYY RDRGSSGWYGWYFDLWGR TLVTVSS CATC TG C A TCTCCATCCTCCCTGTCT CATCTGT GAGACA AGTC CCATCACTTGCCG G A TCAGA CATTAGCAGCTATTT AATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGAT TATGTTGCAT CAGT TGCAAAGTGGGGTCCCATCAAGG TCAGTGGCAG GATCTGGGA AGAT TCAC TC CC T AGTCTGCAACCTGAAGATTTTGCAACT ACTAC TC ACAGAGTTACAGTA CCCCCC ATCACCTTCGGC AAG GA ACGACT GA ATTAAACDIQLTQSPSSLSASVGDRVTIT RA QSISSYLNW QQKP KAPKLLIYV SSLQSGVPSRFSGS SGTDF LTISSLQPEDFATYYCQQSYSTPPI F Q TRLEIK 
Antibody ID IGH VDJ (nt) IGH VDJ (aa) IGL VJ (nt) IGL VJ (aa)
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Extended Data Table 6. Effective and inhibitory concentrations of the monoclonal antibodies
COV21 C002 8.88 21.95 37.61 3.14 >1000
COV21 C003 313.79 992.62 >1000 6.37 >1000
COV21 C004 10.67 41.08 91.71 2.39 >1000
COV21 C005 60.49 130.65 205.20 4.41 >1000
COV21 C006 321.51 >1000 >1000 1.81 >1000
COV21 C008 625.46 >1000 >1000 4.63 >1000
COV21 C009 4.82 14.54 29.34 1.80 >1000
COV21 C010 >1000 >1000 >1000 5.44 >1000
COV21 C013 42.48 360.59 >1000 2.59 >1000
COV21 C016 >1000 >1000 >1000 7.41 >1000
COV21 C017 72.67 256.18 543.87 1.63 >1000
COV21 C018 >1000 >1000 >1000 1.53 >1000
COV21 C019 >1000 >1000 >1000 11.85 >1000
COV21 C021 >1000 >1000 >1000 1.25 >1000
COV21 C022 73.57 314.71 736.87 2.40 5.99
COV21 C027 >1000 >1000 >1000 2.65 696.05
COV21 C029 >1000 >1000 >1000 4.13 >1000
COV21 C030 >1000 >1000 >1000 2.89 >1000
COV21 C031 >1000 >1000 >1000 22.69 >1000
COV107 C101 8.20 30.15 65.30 1.51 >1000
COV107 C102 34.03 84.21 143.23 4.54 >1000
COV107 C103 4.38 12.58 23.59 3.77 >1000
COV107 C104 23.31 72.12 140.28 8.31 >1000
COV107 C105 26.09 72.24 133.70 5.20 >1000
COV107 C106 >1000 >1000 >1000 19.03 106.75
COV107 C107 >1000 >1000 >1000 11.55 >1000
COV107 C108 480.69 >1000 >1000 5.32 >1000
COV107 C110 18.44 45.11 77.28 7.29 >1000
COV107 C112 111.79 701.99 >1000 3.38 >1000
COV107 C113 >1000 >1000 >1000 6.93 >1000
COV107 C114 >1000 >1000 >1000 9.51 >1000
COV107 C115 198.33 958.18 >1000 3.40 >1000
COV107 C116 >1000 >1000 >1000 37.56 >1000
COV107 C117 348.00 >1000 >1000 5.38 >1000
COV107 C118 103.69 417.76 >1000 3.45 3.817
COV107 C119 9.12 39.45 97.78 3.57 >1000
COV107 C120 13.26 26.73 40.30 1.41 >1000
COV107 C121 6.73 14.31 22.33 2.85 >1000
COV107 C122 22.80 57.77 100.12 2.67 >1000
COV107 C123 149.22 355.47 595.51 1.92 >1000
COV107 C124 341.82 937.26 >1000 2.23 >1000
COV107 C125 43.32 92.54 144.26 1.87 >1000
COV107 C126 >1000 >1000 >1000 4.78 >1000
COV107 C127 68.74 190.96 347.31 2.62 >1000
COV072 C128 101.22 263.35 460.73 1.95 >1000
COV072 C130 >1000 >1000 >1000 2.05 >1000
COV072 C131 30.52 178.90 759.11 1.67 >1000
COV072 C132 708.67 >1000 >1000 2.92 >1000
COV072 C133 >1000 >1000 >1000 1.98 >1000
COV072 C134 >1000 >1000 >1000 1.57 >1000
COV072 C135 16.61 32.81 48.90 1.80 >1000
COV072 C136 >1000 >1000 >1000 33.61 >1000
COV072 C137 >1000 >1000 >1000 25.22 >1000
COV072 C138 >1000 >1000 >1000 2.94 >1000
COV072 C139 >1000 >1000 >1000 1.89 >1000
COV072 C140 23.88 66.24 120.69 2.19 >1000
COV072 C141 >1000 >1000 >1000 1.71 >1000
COV047 C143 >1000 >1000 >1000 3.66 >1000
COV047 C144 6.91 17.28 29.66 3.24 >1000
COV047 C145 3.04 14.51 36.79 3.86 >1000
COV047 C146 >1000 >1000 >1000 >1000 >1000
COV047 C147 >1000 >1000 >1000 >1000 >1000
COV047 C148 >1000 >1000 >1000 64.69 >1000
COV047 C150 >1000 >1000 >1000 8.11 >1000
COV047 C151 31.79 363.97 >1000 4.30 >1000
COV047 C153 70.71 490.08 >1000 3.17 >1000
COV047 C154 435.50 >1000 >1000 2.92 10.65
COV047 C155 11.00 35.75 77.01 3.30 >1000
COV047 C156 >1000 >1000 >1000 3.32 >1000
COV047 C164 239.15 865.40 >1000 2.06 >1000
COV072 C165 40.81 138.66 297.38 4.25 >1000
COV96 C201 >1000 >1000 >1000 2.98 >1000
COV96 C202 >1000 >1000 >1000 3.40 >1000
COV96 C204 >1000 >1000 >1000 3.73 9.41
COV96 C205 >1000 >1000 >1000 >1000 >1000
COV96 C207 158.52 960.39 >1000 1.87 >1000
COV96 C208 >1000 >1000 >1000 >1000 >1000
COV96 C209 >1000 >1000 >1000 3.79 >1000
COV96 C210 50.73 155.24 298.90 2.83 >1000
COV96 C211 12.79 34.87 62.89 2.82 >1000
COV96 C212 >1000 >1000 >1000 >1000 >1000
COV96 C214 >1000 >1000 >1000 5.75 >1000
COV96 C215 >1000 >1000 >1000 5.33 17.944
COV96 C216 >1000 >1000 >1000 9.53 >1000
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Extended Data Figures 533 
 534 
Extended Data Figure 1. Clinical correlates. a, Age distribution (Y axis) for all males and 535 
females in the cohort p=0.2074. b, Duration of symptoms in days (Y axis) for all males and females 536 
in the cohort p=0.8704. c, Time between symptom onset and plasma collection (Y axis) for all 537 
males and females in the cohort p=0.5514. d, Subjective symptom severity on a scale of 0-10 (Y 538 
axis) for all males and females in the cohort p=0.1888. e, Age distribution (Y axis) for all cases 539 
and contacts in the cohort p=0.0305. f, Duration of symptoms in days (Y axis) for all cases and 540 
contacts in the cohort p=0.1241. g, Time between symptom onset and plasma collection in days 541 
(Y axis) for all cases and contacts in the cohort p=0.1589. h, Symptom severity (Y axis) for all 542 
cases and contacts in the cohort p=0.0550. i, Age distribution (Y axis) for all outpatient and 543 
hospitalized participants p=0.0024. j, Duration of symptoms in days (Y axis) for all outpatient and 544 
hospitalized participants in the cohort p=<0.0001. k, Time between symptom onset and plasma 545 
collection in days (Y axis) for all outpatient and hospitalized participants in the cohort p=0.0001. 546 
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l, Symptom severity (Y axis) for all outpatient and hospitalized participants in the cohort 547 
p=<0.0001.  Horizontal bars indicate median values. Statistical significance was determined using 548 
two-tailed Mann-Whitney U test.  549 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted May 22, 2020. . https://doi.org/10.1101/2020.05.13.092619doi: bioRxiv preprint 
 550 
Extended Data Figure 2. Clinical correlates of plasma antibody titers. a, AUC for IgG anti-551 
RBD (Y axis) for all cases and contacts in the cohort p=0.0107. b, AUC for IgM anti-RBD (Y 552 
axis) for all cases and contacts in the cohort p=0.5371. c, AUC for IgG anti-S (Y axis) for all cases 553 
and contacts in the cohort p=0.0135. d, AUC for IgM anti-S (Y axis) for all cases and contacts in 554 
the cohort p=0.7838. e, AUC for IgM anti-RBD (Y axis) for all males and females in the cohort 555 
p=0.9597. f, AUC for IgG anti-S (Y axis) for all males and females in the cohort p=0.0275. g, 556 
AUC for IgM anti-S (Y axis) for all males and females in the cohort p=0.5363. h, AUC for IgM 557 
anti-RBD (Y axis) for all outpatient and hospitalized participants in the cohort p=0.0059. i, AUC 558 
for IgG anti-S (Y axis) for all outpatient and hospitalized participants in the cohort p=0.0623. j, 559 
AUC for IgM anti-S (Y axis) for all outpatient and hospitalized participants in the cohort p=0.2976. 560 
Horizontal bars indicate median values. Statistical significance was determined using two-tailed 561 
Mann-Whitney U test.  562 
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 563 
Extended Data Figure 3. Additional clinical correlates of plasma antibody titers. a, Time 564 
between symptom onset and plasma collection in days (X axis) plotted against AUC for IgG anti-565 
RBD (Y axis) r=-0.0261 p=0.7533. b, Time between symptom onset and plasma collection in days 566 
(X axis) plotted against AUC for IgG anti-S (Y axis) r=-0.1495 p=0.0697. c, Time between 567 
symptom onset and plasma collection in days (X axis) plotted against AUC for IgM anti-S (Y axis) 568 
r=0.1496 p=0.0695. d, Age (X axis) plotted against AUC for IgM anti-RBD (Y axis) r=0.0172 569 
p=0.8355. e, Age (X axis) plotted against AUC for IgG anti-S (Y axis) r=0.1523 p=0.0638. f, Age 570 
(X axis) plotted against AUC for IgM anti-S (Y axis) r=0.0565 p=0.4934. g, Duration of symptoms 571 
in days (X axis) plotted against AUC for IgG anti-RBD (Y axis) r=0.1525, p=0.0633. h, Duration 572 
of symptoms in days (X axis) plotted against AUC for IgM anti-RBD (Y axis) r=-0.3187, 573 
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p=<0.0001. i, Duration of symptoms in days (X axis) plotted against AUC for IgG anti-S (Y axis) 574 
r=0.0329, p=0.6904. j, Duration of symptoms in days (X axis) plotted against AUC for IgM anti-575 
S (Y axis) r=0.0824, p=0.3177. k, Severity of symptoms (X axis) plotted against AUC for IgG 576 
anti-RBD (Y axis) r=0.2679 p=0.0010. l, Severity of symptoms (X axis) plotted against AUC for 577 
IgM anti-RBD (Y axis) r=-0.1943 p=0.0176. m, Severity of symptoms (X axis) plotted against 578 
AUC for IgG anti-S (Y axis) r=0.1187 p=0.1492. n, Severity of symptoms (X axis) plotted against 579 
AUC for IgM anti-S (Y axis) r=0.1597 p=0.0517. All correlations were analyzed by two-tailed 580 
Spearman’s.  581 
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 582 
Extended Data Figure 4. Diagrammatic representation of the SARS-CoV2 pseudovirus 583 
luciferase assay. a, Co-transfection of pNL4-3ΔEnv-nanoluc and pSARS-CoV-2 spike vectors 584 
into 293T cells leads to production of SARS-CoV-2 Spike-pseudotyped HIV-1 particles (SARS-585 
CoV-2 pseudovirus) carrying the Nanoluc gene. b, SARS-CoV-2 pseudovirus is incubated for 1 h 586 
at 37°C with plasma or monoclonal antibody dilutions. The virus-antibody mixture is used to infect 587 
ACE2-expressing 293T cells, which will express nanoluc Luciferase upon infection. c, Relative 588 
luminescence units (RLU) reads from lysates of ACE2-expressing 293T cells infected with 589 
increasing amounts of SARS-CoV-2 pseudovirus.  590 
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 591 
Extended Data Figure 5. Clinical correlates of neutralization. a, Anti-RBD IgM AUC (X axis) 592 
plotted against NT50 (Y axis) r=0.3119, p=0.0001. b, Anti-S IgM AUC (X axis) plotted against 593 
NT50 (Y axis) r=0.3211, p=<0.0001. c, Duration of symptoms in days (X axis) plotted against NT50 594 
(Y axis) r=0.1997, p=0.0146. d, Time between symptom onset and plasma collection in days (X 595 
axis) plotted against NT50 (Y axis) r=-0.1344, p=0.1033. e, Symptom severity (X axis) plotted 596 
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against NT50 (Y axis) r=0.2234, p=0.0062. f, Age (X axis) plotted against NT50 (Y axis) r=0.3005, 597 
p=0.0002. All correlations were analyzed by two-tailed Spearman’s. Dotted line (NT50=5) 598 
represents lower limit of detection (LLOD) of pseudovirus neutralization assay. Samples with 599 
undetectable neutralizing titers were plotted at LLOD. 600 
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 602 
Extended Data Figure 6. Flow cytometry. Gating strategy used for cell sorting. Gating was on 603 
singlets that were CD20+ and CD3-CD8-CD16-Ova-. Sorted cells were RBD-PE+ and RBD-604 
AF647+.   605 
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 606 
Extended Data Figure 7. Frequency distributions of human V genes. The two-tailed t test with 607 
unequal variance was used to compare the frequency distributions of human V genes of anti-608 
SARS-CoV-2 antibodies from this study to Sequence Read Archive SRP01097034.  609 
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 610 
Extended Data Figure 8. Analysis of antibody somatic hypermutation and CDR3 length. a, 611 
For each individual, the number of somatic nucleotide mutations (Y axis) at the IGVH and IGVL 612 
are shown on the left panel, and the amino acid length of the CDR3s (Y axis) are shown on the 613 
right panel. The horizontal bar indicated the mean. b, same as in a but for all antibodies combined. 614 
c, Distribution of the hydrophobicity GRAVY scores at the IGH CDR3 in antibody sequences 615 
from this study compared to a public database (see Methods). 616 
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617 
Extended Data Figure 9. Binding of the monoclonal antibodies to the RBD of SARS-CoV-2 618 
and SARS-CoV. a, EC50 values for binding to the RBD of SARS-CoV-2. b and c, Binding curves 619 
and EC50 values for binding to the RBD of SARS-CoV. 620 
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622 
Extended Data Figure 10. Biolayer interferometry experiment. showing binding of antibodies 623 
C144, C101, C002, C121, C009, C019 (see also main text Fig. 4). Graphs show secondary 624 
antibody binding to preformed C121 IgG-RBD complexes. The table displays the shift in 625 
nanometers after second antibody (Ab2) binding to the antigen in the presence of the first antibody 626 
(Ab1). Values are normalized by the subtraction of the autologous antibody control.  627 
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